Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
2'-dATP + 1-phosphatidyl-1D-myo-inositol
2'-dADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
?
ADP + 1-phosphatidyl-1D-myo-inositol
AMP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
12% of the activity with ATP
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
CTP + 1-phosphatidyl-1D-myo-inositol
CDP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
10% of the activity with ATP
-
-
?
dATP + 1-phosphatidyl-1D-myo-inositol
dADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
104% of the activity with ATP
-
-
?
GTP + 1-phosphatidyl-1D-myo-inositol
GDP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
ITP + 1-phosphatidyl-1D-myo-inositol
IDP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
11% of the activity with ATP
-
-
?
TTP + 1-phosphatidyl-1D-myo-inositol
TDP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
3% of the activity with ATP
-
-
?
UTP + 1-phosphatidyl-1D-myo-inositol
UDP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
18% of the activity with ATP
-
-
?
additional information
?
-
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
type III enzymes are responsible for distinct phosphoinositide pools
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
641771, 641777, 641782, 641786, 641787, 641792, 641800, 641806, 641810, 641812, 672504 -
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
PI4K92 is a key enzyme regulating Golgi disintegration/reorganization during mitosis probably via phosphorylation by cyclin-dependent kinases on well-defined sites. PI4K55 is involved in the production of second messengers, diacylglycerol and inositol 1,4,5-triphosphate at the plasma membrane, moreover, in the endocytotic pathway in the cytoplasm
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
phosphorylation of phosphatidylinositol at the D-4 position is an essential step in the biosynthesis of phosphatidylinositolpolyphosphates
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
PI4KIIalpha contributes to the compartment regulation of phosphatidylinositol 4-phosphate synthesis within the Golgi complex
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
PI4KIIIbeta contributes to the compartment regulation of phosphatidylinositol 4-phosphate synthesis within the Golgi complex
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
641768, 641776, 641778, 641779, 641780, 641793, 641794, 641797, 641801, 641806, 641809, 641819, 662814, 672995, 673232, 674704, 674715, 674878, 721555, 721713, 721967, 722121, 723072, 723136, 723609, 723790, 723791, 737789, 738845, 738939, 739030, 758569, 758912, 759586, 759590, 759597 -
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
PI4K92 is a key enzyme regulating Golgi disintegration/reorganization during mitosis probably via phosphorylation by cyclin-dependent kinases on well-defined sites. PI4K55 is involved in the production of second messengers, diacylglycerol and inositol 1,4,5-triphosphate at the plasma membrane, moreover, in the endocytotic pathway in the cytoplasm
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
enzyme is involved in the regulation of endosomal membrane traffic in mammalian cells
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
regulation by Ca2+ may act as a negative feedback system
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
plasma membrane PI4KII is a target of amyloid beta proteins in the pathogenesis of Alzheimers disease
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
type II PtdIns 4-kinase plays a role in lymphocyte infiltration to the sites of inflammation
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
various PI4Ks regulate phosphatidylinositol 4-phosphate synthesis in distinct cellular compartments
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
PI4K92 is a key enzyme regulating Golgi disintegration/reorganization during mitosis probably via phosphorylation by cyclin-dependent kinases on well-defined sites. PI4K55 is involved in the production of second messengers, diacylglycerol and inositol 1,4,5-triphosphate at the plasma membrane, moreover, in the endocytotic pathway in the cytoplasm
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
exocytosis of insulin-containing secretory granules depends on phosphatidylinositol 4-kinase activity. Phosphatidylinositol 4-kinase serves as a metabolic sensor and regulates priming of secretory granules in pancreatic beta cells
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
PI4KIIalpha regulates membrane recruitment and sorting function of AP-3 complexes
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
641769, 641770, 641773, 641789, 641790, 641796, 641802, 641806, 641807, 641812, 641817, 641820, 662444, 662885, 673232 -
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
PI4K92 is a key enzyme regulating Golgi disintegration/reorganization during mitosis probably via phosphorylation by cyclin-dependent kinases on well-defined sites. PI4K55 is involved in the production of second messengers, diacylglycerol and inositol 1,4,5-triphosphate at the plasma membrane, moreover, in the endocytotic pathway in the cytoplasm
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
the enzyme is an integral component of the early signal transduction machinery during T-cell activation by concanavalin A and is actively regulated by protein tyrosine phosphorylation-dephosphorylation
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
generation of 1-phosphatidyl-1D-myo-inositol 4-phosphate by the enzyme on synaptic vesicles may be the first step in the resynthesis of phosphatidylinositol 4,5-bisphosphate
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
phosphatidylinositol 4-kinase is a component of glucose transporter-containing vesicles. It may play a role in defining the fusogenic properties necessary to mediate membrane movement between the glucose transporter vesicles, plasma membranes and micosomes
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
integral componant of FcepsilonRI mediated signal transduction mechanism
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
neuronal calcium sensor-1 and the GTPase ARF1 are localized to the Golgi complex and regulate phosphatidylinositol 4-kinase IIIbeta. Spatial and temporal control of phosphatidylinositol 4-phosphate levels through activation of phosphatidylinositol 4-kinase IIIbeta is important for the recruitment of trafficking complexes to the trans-Golgi network and vesicular traffic from this organelle
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
641775, 641783, 641784, 641785, 641795, 641818, 660950, 674864, 722857, 723790, 723791, 760068 -
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
r
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
reverse reaction is facored in vitro
-
-
r
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
Stt4p activity is required for maintenance of vacuole morphology, cell wall integrity, and actin cytoskeleton organization. In contrast Pik1p is essential for normal secretion, Golgi and vacuole membrane dynamics and endocytosis
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
the enzyme plays a role in endocytic or exocytic pathways
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
?
GTP + 1-phosphatidyl-1D-myo-inositol
GDP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
?
GTP + 1-phosphatidyl-1D-myo-inositol
GDP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
5% of the activity with ATP
-
-
?
GTP + 1-phosphatidyl-1D-myo-inositol
GDP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
?
GTP + 1-phosphatidyl-1D-myo-inositol
GDP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
no activity
-
-
?
additional information
?
-
-
the enzyme possesses autophosphorylation activity but has no detectable lipid kinase activity
-
-
?
additional information
?
-
-
the enzyme isoform PI4Kgamma5 interacts with and phosphorylates the membrane-bound NAC transcription factor ANAC078
-
-
-
additional information
?
-
-
E3 ubiquitin ligase Itch is a binding partner and regulator of PI4KIIalpha function. Itch directly associates with and ubiquitinates PI4KIIa
-
-
?
additional information
?
-
-
PI4KB does not interact with NS5A in hepatitis C virus-infected cells
-
-
?
additional information
?
-
-
the 3A protein from multiple picornaviruses, ncluding Aichi virus, bovine kobuvirus, CVB, HRV14, poliovirus, associates with isozyme PI4KIIIbeta and ACBD3
-
-
?
additional information
?
-
-
the enzyme lacks lipid kinase activity
-
-
-
additional information
?
-
-
Lsb6p binds Las17p, a homologue of the mammalian Wiscott-Aldrich syndrome protein, and WASP
-
-
?
additional information
additional information
-
-
PI4KIIbeta is associated with Hsp90
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
additional information
?
-
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
type III enzymes are responsible for distinct phosphoinositide pools
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
PI4K92 is a key enzyme regulating Golgi disintegration/reorganization during mitosis probably via phosphorylation by cyclin-dependent kinases on well-defined sites. PI4K55 is involved in the production of second messengers, diacylglycerol and inositol 1,4,5-triphosphate at the plasma membrane, moreover, in the endocytotic pathway in the cytoplasm
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
phosphorylation of phosphatidylinositol at the D-4 position is an essential step in the biosynthesis of phosphatidylinositolpolyphosphates
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
PI4KIIalpha contributes to the compartment regulation of phosphatidylinositol 4-phosphate synthesis within the Golgi complex
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
PI4KIIIbeta contributes to the compartment regulation of phosphatidylinositol 4-phosphate synthesis within the Golgi complex
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
721555, 721713, 721967, 722121, 723072, 723136, 723609, 723790, 723791, 737789, 738845, 738939, 739030, 758569, 758912, 759586, 759590, 759597 -
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
PI4K92 is a key enzyme regulating Golgi disintegration/reorganization during mitosis probably via phosphorylation by cyclin-dependent kinases on well-defined sites. PI4K55 is involved in the production of second messengers, diacylglycerol and inositol 1,4,5-triphosphate at the plasma membrane, moreover, in the endocytotic pathway in the cytoplasm
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
enzyme is involved in the regulation of endosomal membrane traffic in mammalian cells
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
regulation by Ca2+ may act as a negative feedback system
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
plasma membrane PI4KII is a target of amyloid beta proteins in the pathogenesis of Alzheimers disease
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
type II PtdIns 4-kinase plays a role in lymphocyte infiltration to the sites of inflammation
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
various PI4Ks regulate phosphatidylinositol 4-phosphate synthesis in distinct cellular compartments
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
PI4K92 is a key enzyme regulating Golgi disintegration/reorganization during mitosis probably via phosphorylation by cyclin-dependent kinases on well-defined sites. PI4K55 is involved in the production of second messengers, diacylglycerol and inositol 1,4,5-triphosphate at the plasma membrane, moreover, in the endocytotic pathway in the cytoplasm
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
exocytosis of insulin-containing secretory granules depends on phosphatidylinositol 4-kinase activity. Phosphatidylinositol 4-kinase serves as a metabolic sensor and regulates priming of secretory granules in pancreatic beta cells
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
PI4KIIalpha regulates membrane recruitment and sorting function of AP-3 complexes
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
PI4K92 is a key enzyme regulating Golgi disintegration/reorganization during mitosis probably via phosphorylation by cyclin-dependent kinases on well-defined sites. PI4K55 is involved in the production of second messengers, diacylglycerol and inositol 1,4,5-triphosphate at the plasma membrane, moreover, in the endocytotic pathway in the cytoplasm
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
the enzyme is an integral component of the early signal transduction machinery during T-cell activation by concanavalin A and is actively regulated by protein tyrosine phosphorylation-dephosphorylation
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
generation of 1-phosphatidyl-1D-myo-inositol 4-phosphate by the enzyme on synaptic vesicles may be the first step in the resynthesis of phosphatidylinositol 4,5-bisphosphate
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
phosphatidylinositol 4-kinase is a component of glucose transporter-containing vesicles. It may play a role in defining the fusogenic properties necessary to mediate membrane movement between the glucose transporter vesicles, plasma membranes and micosomes
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
integral componant of FcepsilonRI mediated signal transduction mechanism
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
neuronal calcium sensor-1 and the GTPase ARF1 are localized to the Golgi complex and regulate phosphatidylinositol 4-kinase IIIbeta. Spatial and temporal control of phosphatidylinositol 4-phosphate levels through activation of phosphatidylinositol 4-kinase IIIbeta is important for the recruitment of trafficking complexes to the trans-Golgi network and vesicular traffic from this organelle
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
Stt4p activity is required for maintenance of vacuole morphology, cell wall integrity, and actin cytoskeleton organization. In contrast Pik1p is essential for normal secretion, Golgi and vacuole membrane dynamics and endocytosis
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
the enzyme plays a role in endocytic or exocytic pathways
-
-
?
ATP + 1-phosphatidyl-1D-myo-inositol
ADP + 1-phosphatidyl-1D-myo-inositol 4-phosphate
-
-
-
-
?
additional information
?
-
-
E3 ubiquitin ligase Itch is a binding partner and regulator of PI4KIIalpha function. Itch directly associates with and ubiquitinates PI4KIIa
-
-
?
additional information
?
-
-
PI4KB does not interact with NS5A in hepatitis C virus-infected cells
-
-
?
additional information
?
-
-
the 3A protein from multiple picornaviruses, ncluding Aichi virus, bovine kobuvirus, CVB, HRV14, poliovirus, associates with isozyme PI4KIIIbeta and ACBD3
-
-
?
additional information
?
-
-
Lsb6p binds Las17p, a homologue of the mammalian Wiscott-Aldrich syndrome protein, and WASP
-
-
?
additional information
additional information
-
-
PI4KIIbeta is associated with Hsp90
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(1'R)-2'-acetyl-N-(2-fluorophenyl)-1'-(hydroxymethyl)-7'-methoxy-1',2',3',9'-tetrahydrospiro[piperidine-4,4'-pyrido[3,4-b]indole]-1-carboxamide
(1-((5-(6-chloro-8-(((2-ethylpyridin-4-yl)methyl)amino)-2-methylimidazo[1,2-b]pyridazin-3-yl)-2-methoxyphenyl)sulfonyl)-piperidin-4-yl)methanol
-
(1R)-3-[3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonyl]cyclopentan-1-ol
-
-
(2-bromo-4,5-dimethoxyphenyl)(6,7-dimethoxyisoquinolin-1-yl)methanone
-
about 80% residual activity at 0.01 mM
(3-aminopyrrolidin-1-yl)(4-[5-amino-6-[6-(trifluoromethyl)pyridin-3-yl]pyrazin-2-yl]phenyl)methanone
-
-
(3R)-1-[3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonyl]pyrrolidin-3-ol
(4-[3-[4-(methanesulfonyl)phenyl]imidazo[1,2-b]pyridazin-6-yl]phenyl)(piperazin-1-yl)methanone
-
-
(4-[5-amino-6-[4-(trifluoromethyl)phenyl]pyrazin-2-yl]phenyl)(3-hydroxypyrrolidin-1-yl)methanone
-
-
(4-[5-amino-6-[4-(trifluoromethyl)phenyl]pyrazin-2-yl]phenyl)(piperazin-1-yl)methanone
-
-
(4-[5-amino-6-[4-(trifluoromethyl)phenyl]pyrazin-2-yl]phenyl)[(3R)-3-hydroxypyrrolidin-1-yl]methanone
-
-
(4-[5-amino-6-[4-(trifluoromethyl)phenyl]pyrazin-2-yl]phenyl)[(3S)-3-hydroxypyrrolidin-1-yl]methanone
-
-
(4-[5-amino-6-[6-(trifluoromethyl)pyridin-3-yl]pyrazin-2-yl]phenyl)(piperazin-1-yl)methanone
-
-
(4-[6-[3-(methanesulfonyl)phenyl]imidazo[1,2-b]pyridazin-3-yl]phenyl)(piperazin-1-yl)methanone
-
-
1,10-phenanthroline-5,6-dione
-
about 35% residual activity at 0.01 mM
1,6-dimethyl-3-propylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione
-
about 65% residual activity at 0.01 mM
1-[3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonyl]piperidin-4-ol
1-[3-[9-(3,4-dimethoxyphenyl)-8-methyl-6-[[2-(morpholin-4-yl)ethyl]amino]-9H-purin-2-yl]phenyl]-2-methylpropan-1-one
-
16% residual activity at 0.01 mM
1-[5-(6-chloro-8-[[(2-ethylpyridin-4-yl)methyl]amino]-2-methylimidazo[1,2-b]pyridazin-3-yl)-2-methoxybenzene-1-sulfonyl]piperidin-4-ol
-
2'(3')-O-(2,4,6-Trinitrophenyl)ATP
-
-
2,3-Dihydroxybenzaldehyde
-
-
2-(3-chlorophenyl)-9-(3,4-dimethoxyphenyl)-8-methyl-N-[2-(morpholin-4-yl)ethyl]-9H-purin-6-amine
-
67% residual activity at 0.01 mM
2-(4-methylpiperazin-1-yl)-8-(pyridin-4-yl)-1,5-naphthyridine
2-([3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]phenyl]sulfonyl)ethanol
2-amino-1-(isopropylsulfonyl)-6-benzimidazole phenylketone oxime
-
i.e. enviroxime, inhibitor of the in vitro replication of rhinoviruses and enteroviruses, inhibits hepatitis C virus subgenomic replicon replication
2-ethoxy-6'-methoxy-5-[4-(methylsulfonyl)phenyl]-3,3'-bipyridine
-
-
2-fluoro-5-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzamide
2-iodo-6'-methoxy-5-[4-(methylsulfonyl)phenyl]-3,3'-bipyridine
-
-
2-[3-(benzylsulfanyl)phenyl]-8-(pyridin-4-yl)-1,5-naphthyridine
2-[3-(methylsulfonyl)phenyl]-8-(piperazin-1-yl)-1,5-naphthyridine
2-[3-(methylsulfonyl)phenyl]-8-(pyridin-4-yl)-1,5-naphthyridine
2-[3-(phenylsulfanyl)phenyl]-8-(pyridin-4-yl)-1,5-naphthyridine
-
-
2-[3-(piperidine-1-sulfonyl)phenyl]-8-(pyridin-4-yl)-1,5-naphthyridine
2-[3-[(3R,5S)-3,5-dimethylpiperazine-1-sulfonyl]phenyl]-8-(pyridin-4-yl)-1,5-naphthyridine
2-[5-(1,3-benzodioxol-5-yl)-1,2,4-oxadiazol-3-yl]pyridine
-
about 18% residual activity at 0.01 mM
2-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
2-[[7-(3,4-dimethoxyphenyl)quinoxalin-2-yl]amino]-N-methylacetamide
3-(1-methyl-1H-benzimidazol-5-yl)-6-[3-(propane-2-sulfonyl)phenyl]imidazo[1,2-b]pyridazine
-
-
3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-[2-(morpholin-4-yl)ethyl]pyrazolo[1,5-a]pyrimidin-7-amine
3-(3,4-dimethoxyphenyl)-5-methyl-N-[2-(morpholin-4-yl)ethyl]-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-amine
-
31% residual activity at 0.01 mM
3-(3,4-dimethoxyphenyl)-N-[2-(morpholin-4-yl)ethyl]-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-amine
-
41% residual activity at 0.01 mM
3-(4-methylphenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
about 55% residual activity at 0.01 mM
3-(6-chloro-2-methyl-8-[[(2-methylpyridin-4-yl)methyl]amino]imidazo[1,2-b]pyridazin-3-yl)-N,N-dimethylbenzene-1-sulfonamide
-
3-(6-chloro-2-methyl-8-[[(pyridin-3-yl)methyl]amino]imidazo[1,2-b]pyridazin-3-yl)-N,N-dimethylbenzene-1-sulfonamide
-
3-(6-chloro-2-methyl-8-[[(pyridin-4-yl)methyl]amino]imidazo[1,2-b]pyridazin-3-yl)-N,N-dimethylbenzene-1-sulfonamide
-
3-(6-chloro-8-[[(2-ethylpyridin-4-yl)methyl]amino]-2-methylimidazo[1,2-b]pyridazin-3-yl)-N,N-dimethylbenzene-1-sulfonamide
-
3-(6-methoxypyridin-3-yl)-5-[4-(methylsulfonyl)-2-(trifluoromethyl)phenyl]pyrazin-2-amine
-
-
3-(6-methoxypyridin-3-yl)-5-[4-(methylsulfonyl)phenyl]pyrazin-2-amine
-
-
3-(6-methoxypyridin-3-yl)-5-[4-(trifluoromethoxy)phenyl]pyrazin-2-amine
-
-
3-(8-phenyl-1,5-naphthyridin-2-yl)benzenesulfonamide
3-[4-(methylsulfonyl)phenyl]-6-[2-(trifluoromethyl)pyridin-4-yl]imidazo[1,2-b]pyridazine
-
-
3-[4-(methylsulfonyl)phenyl]-6-[3-(trifluoromethyl)phenyl]imidazo[1,2-b]pyridazine
-
-
3-[8-(1H-pyrazol-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
3-[8-(3-fluoropyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
3-[8-(4-benzylpiperazin-1-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
3-[8-(4-methylpiperazin-1-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
3-[8-(6-methylpyridin-3-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
3-[8-(pyridin-3-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]-N-[2-(pyrrolidin-1-yl)ethyl]benzene-1-sulfonamide
3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]aniline
3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzamide
3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
3-[8-[2-(trifluoromethyl)pyridin-4-yl]-1,5-naphthyridin-2-yl]benzenesulfonamide
3-[8-[4-(trifluoromethyl)phenyl]-1,5-naphthyridin-2-yl]benzenesulfonamide
4-(quinoxalin-2-yl)phenyl furan-2-carboxylate
-
about 75% residual activity at 0.01 mM
4-fluoro-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzamide
4-[5-amino-6-[6-(trifluoromethyl)pyridin-3-yl]pyrazin-2-yl]benzoic acid
-
-
4-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
4-[9-(3,4-dimethoxyphenyl)-2-methyl-6-[[2-(morpholin-4-yl)ethyl]amino]-9H-purin-8-yl]benzonitrile
-
97% residual activity at 0.01 mM
4-[9-(3,4-dimethoxyphenyl)-8-methyl-6-[[2-(morpholin-4-yl)ethyl]amino]-9H-purin-2-yl]benzonitrile
-
97% residual activity at 0.01 mM
4-[9-(3,4-dimethoxyphenyl)-8-methyl-6-[[2-(morpholin-4-yl)ethyl]amino]-9H-purin-2-yl]phenol
-
18% residual activity at 0.01 mM
5'-AMP
-
0.5 mM, 10% inhibition
5,5'-dithiobis(2-nitrobenzoate)
-
0.03 mM, 10 min, 95% inhibition
5-(6-chloro-8-[[(2-ethylpyridin-4-yl)methyl]amino]-2-methylimidazo[1,2-b]pyridazin-3-yl)-2-methoxy-N,N-dimethylbenzene-1-sulfonamide
-
5-(6-chloro-8-[[(2-ethylpyridin-4-yl)methyl]amino]-2-methylimidazo[1,2-b]pyridazin-3-yl)-2-methoxy-N-(2-methoxyethyl)benzene-1-sulfonamide
-
5-(6-chloro-8-[[(2-ethylpyridin-4-yl)methyl]amino]-2-methylimidazo[1,2-b]pyridazin-3-yl)-2-methoxy-N-(prop-2-en-1-yl)benzene-1-sulfonamide
-
5-(6-chloro-8-[[(2-ethylpyridin-4-yl)methyl]amino]-2-methylimidazo[1,2-b]pyridazin-3-yl)-2-methoxybenzene-1-sulfonyl chloride
-
5-(6-chloro-8-[[(2-ethylpyridin-4-yl)methyl]amino]-2-methylimidazo[1,2-b]pyridazin-3-yl)-N-(1-hydroxybutan-2-yl)-2-methoxybenzene-1-sulfonamide
-
5-(6-chloro-8-[[(2-ethylpyridin-4-yl)methyl]amino]-2-methylimidazo[1,2-b]pyridazin-3-yl)-N-(2-hydroxyethyl)-2-methoxybenzene-1-sulfonamide
-
5-(6-chloro-8-[[(2-ethylpyridin-4-yl)methyl]amino]-2-methylimidazo[1,2-b]pyridazin-3-yl)-N-cyclopropyl-2-methoxybenzene-1-sulfonamide
-
5-(6-chloro-8-[[(2-ethylpyridin-4-yl)methyl]amino]-2-methylimidazo[1,2-b]pyridazin-3-yl)-N-[2-(dimethylamino)ethyl]-2-methoxybenzene-1-sulfonamide
-
5-[4-(methylsulfonyl)phenyl]-3-[6-(trifluoromethyl)pyridin-3-yl]pyrazin-2-amine
-
-
5-[4-(methylsulfonyl)phenyl]-6'-(trifluoromethyl)-3,3'-bipyridin-2-amine
5-[8-(1H-pyrazol-4-yl)-1,5-naphthyridin-2-yl]pyridine-3-sulfonamide
5-[8-(4-cyanophenyl)-1,5-naphthyridin-2-yl]pyridine-3-sulfonamide
5-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]pyridine-3-sulfonamide
5-[8-[(2-acetamidoethyl)amino]-6-chloro-2-methylimidazo[1,2-b]pyridazin-3-yl]-2-methoxybenzene-1-sulfonyl chloride
-
5-[8-[4-(trifluoromethoxy)phenyl]-1,5-naphthyridin-2-yl]pyridine-3-sulfonamide
6-(3-methylphenyl)-3-(6-methylpyridin-3-yl)imidazo[1,2-b]pyridazine
-
-
6-chloro-3-iodo-2-methyl-N-((2-methylpyridin-4-yl)methyl)-imidazo[1,2-b]pyridazin-8-amine
-
6-chloro-3-iodo-2-methyl-N-(pyridin-2-ylmethyl)imidazo[1,2-b]-pyridazin-8-amine
-
6-chloro-3-iodo-2-methyl-N-(pyridin-3-ylmethyl)imidazo[1,2-b]-pyridazin-8-amine
-
6-chloro-3-iodo-2-methyl-N-(pyridin-4-ylmethyl)imidazo[1,2-b]-pyridazin-8-amine
-
6-chloro-N-((2-ethylpyr idin-4-yl)methyl)-3-iodo-2-methylimidazo[1,2-b]pyridazin-8-amine
-
6-chloro-N-[(2-ethylpyridin-4-yl)methyl]-3-(4-methoxyphenyl)-2-methylimidazo[1,2-b]pyridazin-8-amine
-
6-chloro-N-[(2-ethylpyridin-4-yl)methyl]-3-[4-methoxy-3-(1H-pyrazole-1-sulfonyl)phenyl]-2-methylimidazo[1,2-b]pyridazin-8-amine
-
6-chloro-N-[(2-ethylpyridin-4-yl)methyl]-3-[4-methoxy-3-(morpholine-4-sulfonyl)phenyl]-2-methylimidazo[1,2-b]pyridazin-8-amine
-
6-chloro-N-[(2-ethylpyridin-4-yl)methyl]-3-[4-methoxy-3-(piperidine-1-sulfonyl)phenyl]-2-methylimidazo[1,2-b]pyridazin-8-amine
-
6-[3-(methylsulfonyl)phenyl]-3-[4-(methylsulfonyl)phenyl]imidazo[1,2-a]pyridine
-
-
6-[3-(methylsulfonyl)phenyl]-3-[4-(methylsulfonyl)phenyl]imidazo[1,2-a]pyrimidine
-
-
6-[3-(methylsulfonyl)phenyl]-3-[4-(methylsulfonyl)phenyl]imidazo[1,2-b]pyridazine
-
-
6-[4-(cyclopropylsulfonyl)phenyl]-3-[4-(methylsulfonyl)phenyl]imidazo[1,2-b]pyridazine
-
-
7-(3,4-dimethoxyphenyl)-N-[2-(morpholin-4-yl)ethyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
-
74% residual activity at 0.01 mM
8-(cyclohex-3-en-1-yl)-9-(3,4-dimethoxyphenyl)-2-methyl-N-[2-(morpholin-4-yl)ethyl]-9H-purin-6-amine
-
75% residual activity at 0.01 mM
8-(pyridin-4-yl)-2-[3-(pyrrolidin-1-ylsulfonyl)phenyl]-1,5-naphthyridine
8-(pyridin-4-yl)-2-[5-(trifluoromethyl)pyridin-3-yl]-1,5-naphthyridine
8-bromo-9-(3,4-dimethoxyphenyl)-2-methyl-N-[2-(morpholin-4-yl)ethyl]-9H-purin-6-amine
-
17% residual activity at 0.01 mM
8-cyclohexyl-9-(3,4-dimethoxyphenyl)-2-methyl-N-[2-(morpholin-4-yl)ethyl]-9H-purin-6-amine
-
79% residual activity at 0.01 mM
9-(3,4-dimethoxyphenyl)-2,8-dimethyl-N-[2-(morpholin-4-yl)ethyl]-5,9-dihydro-4H-purin-6-amine
-
14% residual activity at 0.01 mM
9-(3,4-dimethoxyphenyl)-2-(4-fluorophenyl)-8-methyl-N-[2-(morpholin-4-yl)ethyl]-9H-purin-6-amine
-
66% residual activity at 0.01 mM
9-(3,4-dimethoxyphenyl)-2-ethynyl-8-methyl-N-[2-(morpholin-4-yl)ethyl]-9H-purin-6-amine
-
18% residual activity at 0.01 mM
9-(3,4-dimethoxyphenyl)-2-iodo-8-methyl-N-[2-(morpholin-4-yl)ethyl]-9H-purin-6-amine
-
33% residual activity at 0.01 mM
9-(3,4-dimethoxyphenyl)-2-methoxy-8-methyl-N-[2-(morpholin-4-yl)ethyl]-9H-purin-6-amine
-
15% residual activity at 0.01 mM
9-(3,4-dimethoxyphenyl)-2-methyl-N-[2-(morpholin-4-yl)ethyl]-8-(3-phenylprop-1-yn-1-yl)-9H-purin-6-amine
-
96% residual activity at 0.01 mM
9-(3,4-dimethoxyphenyl)-2-methyl-N-[2-(morpholin-4-yl)ethyl]-8-(propan-2-yl)-9H-purin-6-amine
-
65% residual activity at 0.01 mM
9-(3,4-dimethoxyphenyl)-2-methyl-N-[2-(morpholin-4-yl)ethyl]-8-(thiophen-3-yl)-9H-purin-6-amine
-
94% residual activity at 0.01 mM
9-(3,4-dimethoxyphenyl)-2-methyl-N-[2-(morpholin-4-yl)ethyl]-8-(trifluoromethyl)-9H-purin-6-amine
-
99% residual activity at 0.01 mM
9-(3,4-dimethoxyphenyl)-2-methyl-N-[2-(morpholin-4-yl)ethyl]-9H-purin-6-amine
-
26% residual activity at 0.01 mM
9-(3,4-dimethoxyphenyl)-8-(4-fluorophenyl)-2-methyl-N-[2-(morpholin-4-yl)ethyl]-9H-purin-6-amine
-
78% residual activity at 0.01 mM
9-(3,4-dimethoxyphenyl)-8-iodo-2-methyl-N-[2-(morpholin-4-yl)ethyl]-9H-purin-6-amine
-
38% residual activity at 0.01 mM
9-(3,4-dimethoxyphenyl)-8-methoxy-2-methyl-N-[2-(morpholin-4-yl)ethyl]-9H-purin-6-amine
-
86% residual activity at 0.01 mM
9-(3,4-dimethoxyphenyl)-8-methyl-6-[[2-(morpholin-4-yl)ethyl]amino]-9H-purine-2-carbonitrile
-
24% residual activity at 0.01 mM
9-(3,4-dimethoxyphenyl)-8-methyl-N-[2-(morpholin-4-yl)ethyl]-2-(3-phenylprop-1-yn-1-yl)-9H-purin-6-amine
-
58% residual activity at 0.01 mM
9-(3,4-dimethoxyphenyl)-8-methyl-N-[2-(morpholin-4-yl)ethyl]-2-(pyridin-3-yl)-9H-purin-6-amine
-
36% residual activity at 0.01 mM
9-(3,4-dimethoxyphenyl)-8-methyl-N-[2-(morpholin-4-yl)ethyl]-2-(thiophen-3-yl)-9H-purin-6-amine
-
46% residual activity at 0.01 mM
9-(3,4-dimethoxyphenyl)-8-methyl-N-[2-(morpholin-4-yl)ethyl]-9H-purin-6-amine
-
13% residual activity at 0.01 mM
9-(3,4-dimethoxyphenyl)-8-methyl-N6-[2-(morpholin-4-yl)ethyl]-9H-purine-2,6-diamine
-
25% residual activity at 0.01 mM
amyloid beta
-
amino acids 1-42, inhibits type II phosphatidylinositol 4-kinase and enhances glutamate toxicity
-
amyloid beta protein
-
pathophysiological concentrations of amyloid beta proteins directly inhibit. Abeta25-35 inhibits in a non-competitive manner. Inhibition by 10 nM Abeta25-35 is reversible
-
amyloid beta protein 2-42
-
10 nM
-
amyloid beta protein 25-35
-
10 nM, 78% residual activity
-
arachidonic acid
-
0.5 mg/ml, 91.3% inhibition of mPIK-III
Caffeine
-
6.5 mM, 18% inhibition
cetyltrimethylammonium bromide
-
-
cholesterol
-
cholesterol sensitivity of PI4KIIalpha
Cu2+
-
0.25 mM CuCl2, complete inhibition
GMP
-
1 mM, 20% inhibition
guanosine
-
1 mM, 50% inhibition
HgCl2
-
5 mM, complete inhibition
inosithin
-
a commercial preparation of ethanol-insoluble phospholipids from soybean; at high concentration
iodoacetate
-
0.1 mM, complete loss of activity
La3+
-
0.2 mM, 78% inhibition
Lubrol Px
-
1%, 72% inhibition
Ly-294002
-
IC50: 0.05-0.1 mM; IC50: 0.1 mM
MDL-860
-
irreversible inhibition. MDL-860 only affects in vivo isoform PI4KB activity
methyl N-[[(4-butyl-2-oxo-2H-1-benzopyran-7-yl)oxy]acetyl]-5-hydroxy-L-tryptophanate
-
-
N'-(4-methoxybenzoyl)pyridine-2-carbohydrazide
-
about 20% residual activity at 0.01 mM
N'-[(4-methoxybenzoyl)oxy]pyridine-2-carboximidamide
-
about 30% residual activity at 0.01 mM
N,N-dimethyl-8-(pyridin-4-yl)-1,5-naphthyridin-2-amine
N-(1H-benzimidazol-2-yl)-2-methoxybenzamide
-
about 65% residual activity at 0.01 mM
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-[[5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazol-2-yl]sulfanyl]acetamide
-
about 40% residual activity at 0.01 mM
N-(2-((3-(3-((1H-pyrazol-1-yl)sulfonyl)-4-methoxyphenyl)-6-chloro-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)ethyl)-acetamide
-
N-(2-((3-(3-(N-(4-aminocyclohexyl)sulfamoyl)-4-methoxyphenyl)-6-chloro-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)ethyl)-acetamide
-
N-(2-((3-(3-(N-allylsulfamoyl)-4-methoxyphenyl)-6-chloro-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)ethyl)acetamide
-
N-(2-((6-chloro-3-(3-((4-(hydroxymethyl)piperidin-1-yl)sulfonyl)-4-methoxyphenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)-ethyl)acetamide
-
N-(2-((6-chloro-3-(3-(N,N-dimethylsulfamoyl)-4-methoxyphenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)ethyl)acetamide
-
N-(2-((6-chloro-3-(3-(N-(1-hydroxybutan-2-yl)sulfamoyl)-4-methoxyphenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)ethyl)-acetamide
-
N-(2-((6-chloro-3-(3-(N-(2-(dimethylamino)ethyl)sulfamoyl)-4-methoxyphenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)-ethyl)acetamide
-
N-(2-((6-chloro-3-(3-(N-(2-hydroxyethyl)sulfamoyl)-4-methoxyphenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)ethyl)-acetamide
-
N-(2-((6-chloro-3-(3-(N-cyclopropylsulfamoyl)-4-methoxyphenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)ethyl)acetamide
-
N-(2-((6-chloro-3-(4-methoxy-3-(morpholinosulfonyl)phenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)ethyl)acetamide
-
N-(2-((6-chloro-3-(4-methoxy-3-(N-(2-methoxyethyl)sulfamoyl)-phenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)ethyl)-acetamide
-
N-(2-((6-chloro-3-(4-methoxy-3-(N-methyl-N-(2-(methylamino)-ethyl)sulfamoyl)phenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)-amino)ethyl)acetamide
-
N-(2-((6-chloro-3-(4-methoxy-3-(piperidin-1-ylsulfonyl)phenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)ethyl)acetamide
-
N-(2-((6-chloro-3-(4-methoxyphenyl)-2-methylimidazo[1,2-b]-pyridazin-8-yl)amino)ethyl)acetamide
-
N-(2-((6-chloro-3-iodo-2-methylimidazo[1,2-b]pyridazin-8-yl)-amino)ethyl)acetamide
-
N-(2-hydroxyethyl)-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
N-(2-hydroxyethyl)-3-[8-[4-(trifluoromethoxy)phenyl]-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
N-(3-aminopropyl)-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
N-(3-hydroxypropyl)-4-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
N-(4-aminocyclohexyl)-5-(6-chloro-8-[[(2-ethylpyridin-4-yl)methyl]amino]-2-methylimidazo[1,2-b]pyridazin-3-yl)-2-methoxybenzene-1-sulfonamide
-
N-(4-chlorophenyl)-N-methyl-3-[4-(methylcarbamoyl)phenyl]imidazo[1,2-a]pyrazine-6-carboxamide
N-(4-cyanophenyl)-N-methyl-3-[4-(trifluoromethyl)phenyl]imidazo[1,2-a]pyrazine-6-carboxamide
-
KAI407
N-(5-[4-chloro-3-[(2-hydroxyethyl)sulfamoyl]phenyl]-4-methyl-1,3-thiazol-2-yl)acetamide
-
i.e. PIK93, a phenylthiazole
N-benzyl-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
N-cyclopropyl-8-(pyridin-4-yl)-1,5-naphthyridin-2-amine
N-[(2S)-1-hydroxypropan-2-yl]-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
N-[(oxetan-3-yl)methyl]-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
N-[2-(dimethylamino)ethyl]-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzamide
N-[2-(morpholin-4-yl)ethyl]-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
N-[2-(piperidin-1-yl)ethyl]-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzamide
N-[2-(pyrrolidin-1-yl)ethyl]-3-[8-[2-(trifluoromethyl)pyridin-4-yl]-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
N-[2-([6-chloro-3-[3-(dimethylsulfamoyl)phenyl]-2-methylimidazo[1,2-b]pyridazin-8-yl]amino)ethyl]acetamide
-
N-[3-(methylsulfonyl)phenyl]-8-(pyridin-4-yl)-1,5-naphthyridin-2-amine
N-[3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]phenyl]methanesulfonamide
N-[3-[9-(3,4-dimethoxyphenyl)-8-methyl-6-[[2-(morpholin-4-yl)ethyl]amino]-9H-purin-2-yl]phenyl]acetamide
-
14% residual activity at 0.01 mM
N-[5-[4-(dimethylamino)phenyl]-3-oxo-2,3-dihydro-1H-pyrazol-4-yl]pyridine-2-carboxamide
-
about 95% residual activity at 0.01 mM
N-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]methanesulfonamide
N-[[(4-butyl-2-oxo-2H-1-benzopyran-7-yl)oxy]acetyl]-5-hydroxy-L-tryptophan
-
about 20% residual activity at 0.01 mM
N6-dimethylamine-adenosine 5'-triphosphate
NVP-BGT226
complete inhibition at 0.01 mM
PAO
-
inhibitor of type III PI4Ks, with greater specificity for PI4KIIIalpha than for PI4KIIIbeta
phosphate
-
20 mM, 50% inhibition
phosphatidic acid
-
slight
phosphatidylinositol 4,5-bisphosphate
phosphatidylinositol 4-phosphate
propan-2-yl N-[[(4-butyl-2-oxo-2H-1-benzopyran-7-yl)oxy]acetyl]-5-hydroxy-L-tryptophanate
-
-
resveratrol
inhibition of PtdIns 4-kinase activity by resveratrol/phenylarsine oxide reduces Jurkat cell adhesion to matrigel/fibronectin coated surfaces
sodium cholate
-
inhibits activity of both mPIK-I and mPIK-III
Sodium mersalyl
-
0.1 mM, 78% inhibition
tert-butyl N-[[8-(2-chlorophenyl)-4,5-dihydro[1,3]thiazolo[4,5-h]quinazolin-2-yl]carbamoyl]-beta-alaninate
-
i.e. Inhibitor A
theophylline
-
2 mM, 21% inhibition
Toyocamycin
-
IC50 is 0.0033 mg/ml
[(3R)-3-aminopyrrolidin-1-yl](4-[5-amino-6-[4-(trifluoromethyl)phenyl]pyrazin-2-yl]phenyl)methanone
-
-
[(3S)-3-aminopyrrolidin-1-yl](4-[5-amino-6-[4-(trifluoromethyl)phenyl]pyrazin-2-yl]phenyl)methanone
-
-
[5-(4-[[4-(morpholin-4-yl)phenyl]amino]quinazolin-6-yl)furan-2-yl]methanol
[9-(3,4-dimethoxyphenyl)-2-methyl-6-[[2-(morpholin-4-yl)ethyl]amino]-9H-purin-8-yl]methanol
-
62% residual activity at 0.01 mM
(1'R)-2'-acetyl-N-(2-fluorophenyl)-1'-(hydroxymethyl)-7'-methoxy-1',2',3',9'-tetrahydrospiro[piperidine-4,4'-pyrido[3,4-b]indole]-1-carboxamide
-
BRD73842
(1'R)-2'-acetyl-N-(2-fluorophenyl)-1'-(hydroxymethyl)-7'-methoxy-1',2',3',9'-tetrahydrospiro[piperidine-4,4'-pyrido[3,4-b]indole]-1-carboxamide
-
BRD73842
(3R)-1-[3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonyl]pyrrolidin-3-ol
-
-
(3R)-1-[3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonyl]pyrrolidin-3-ol
-
-
1-[3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonyl]piperidin-4-ol
-
-
1-[3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonyl]piperidin-4-ol
-
-
2-(4-methylpiperazin-1-yl)-8-(pyridin-4-yl)-1,5-naphthyridine
-
-
2-(4-methylpiperazin-1-yl)-8-(pyridin-4-yl)-1,5-naphthyridine
-
-
2-([3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]phenyl]sulfonyl)ethanol
-
-
2-([3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]phenyl]sulfonyl)ethanol
-
-
2-fluoro-5-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzamide
-
-
2-fluoro-5-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzamide
-
-
2-[3-(benzylsulfanyl)phenyl]-8-(pyridin-4-yl)-1,5-naphthyridine
-
-
2-[3-(benzylsulfanyl)phenyl]-8-(pyridin-4-yl)-1,5-naphthyridine
-
-
2-[3-(methylsulfonyl)phenyl]-8-(piperazin-1-yl)-1,5-naphthyridine
-
-
2-[3-(methylsulfonyl)phenyl]-8-(piperazin-1-yl)-1,5-naphthyridine
-
-
2-[3-(methylsulfonyl)phenyl]-8-(pyridin-4-yl)-1,5-naphthyridine
-
-
2-[3-(methylsulfonyl)phenyl]-8-(pyridin-4-yl)-1,5-naphthyridine
-
-
2-[3-(piperidine-1-sulfonyl)phenyl]-8-(pyridin-4-yl)-1,5-naphthyridine
-
-
2-[3-(piperidine-1-sulfonyl)phenyl]-8-(pyridin-4-yl)-1,5-naphthyridine
-
-
2-[3-[(3R,5S)-3,5-dimethylpiperazine-1-sulfonyl]phenyl]-8-(pyridin-4-yl)-1,5-naphthyridine
-
-
2-[3-[(3R,5S)-3,5-dimethylpiperazine-1-sulfonyl]phenyl]-8-(pyridin-4-yl)-1,5-naphthyridine
-
-
2-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
-
-
2-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
-
-
2-[[7-(3,4-dimethoxyphenyl)quinoxalin-2-yl]amino]-N-methylacetamide
-
BQR695
2-[[7-(3,4-dimethoxyphenyl)quinoxalin-2-yl]amino]-N-methylacetamide
-
BQR695
3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-[2-(morpholin-4-yl)ethyl]pyrazolo[1,5-a]pyrimidin-7-amine
-
-
3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-[2-(morpholin-4-yl)ethyl]pyrazolo[1,5-a]pyrimidin-7-amine
-
3-(8-phenyl-1,5-naphthyridin-2-yl)benzenesulfonamide
-
-
3-(8-phenyl-1,5-naphthyridin-2-yl)benzenesulfonamide
-
-
3-[8-(1H-pyrazol-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
-
-
3-[8-(1H-pyrazol-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
-
-
3-[8-(3-fluoropyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
-
-
3-[8-(3-fluoropyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
-
-
3-[8-(4-benzylpiperazin-1-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
-
-
3-[8-(4-benzylpiperazin-1-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
-
-
3-[8-(4-methylpiperazin-1-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
-
-
3-[8-(4-methylpiperazin-1-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
-
-
3-[8-(6-methylpyridin-3-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
-
-
3-[8-(6-methylpyridin-3-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
-
-
3-[8-(pyridin-3-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
-
-
3-[8-(pyridin-3-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
-
-
3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]-N-[2-(pyrrolidin-1-yl)ethyl]benzene-1-sulfonamide
-
-
3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]-N-[2-(pyrrolidin-1-yl)ethyl]benzene-1-sulfonamide
-
-
3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]aniline
-
-
3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]aniline
-
-
3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzamide
-
-
3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzamide
-
-
3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
-
-
3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
-
-
3-[8-[2-(trifluoromethyl)pyridin-4-yl]-1,5-naphthyridin-2-yl]benzenesulfonamide
-
-
3-[8-[2-(trifluoromethyl)pyridin-4-yl]-1,5-naphthyridin-2-yl]benzenesulfonamide
-
-
3-[8-[4-(trifluoromethyl)phenyl]-1,5-naphthyridin-2-yl]benzenesulfonamide
-
-
3-[8-[4-(trifluoromethyl)phenyl]-1,5-naphthyridin-2-yl]benzenesulfonamide
-
-
4-fluoro-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzamide
-
-
4-fluoro-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzamide
-
-
4-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
-
-
4-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
-
-
5-[4-(methylsulfonyl)phenyl]-6'-(trifluoromethyl)-3,3'-bipyridin-2-amine
-
MMV390048
5-[4-(methylsulfonyl)phenyl]-6'-(trifluoromethyl)-3,3'-bipyridin-2-amine
-
MMV390048
5-[8-(1H-pyrazol-4-yl)-1,5-naphthyridin-2-yl]pyridine-3-sulfonamide
-
MMV024101
5-[8-(1H-pyrazol-4-yl)-1,5-naphthyridin-2-yl]pyridine-3-sulfonamide
-
MMV024101
5-[8-(4-cyanophenyl)-1,5-naphthyridin-2-yl]pyridine-3-sulfonamide
-
-
5-[8-(4-cyanophenyl)-1,5-naphthyridin-2-yl]pyridine-3-sulfonamide
-
-
5-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]pyridine-3-sulfonamide
-
-
5-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]pyridine-3-sulfonamide
-
-
5-[8-[4-(trifluoromethoxy)phenyl]-1,5-naphthyridin-2-yl]pyridine-3-sulfonamide
-
-
5-[8-[4-(trifluoromethoxy)phenyl]-1,5-naphthyridin-2-yl]pyridine-3-sulfonamide
-
-
8-(pyridin-4-yl)-2-[3-(pyrrolidin-1-ylsulfonyl)phenyl]-1,5-naphthyridine
-
-
8-(pyridin-4-yl)-2-[3-(pyrrolidin-1-ylsulfonyl)phenyl]-1,5-naphthyridine
-
-
8-(pyridin-4-yl)-2-[5-(trifluoromethyl)pyridin-3-yl]-1,5-naphthyridine
-
-
8-(pyridin-4-yl)-2-[5-(trifluoromethyl)pyridin-3-yl]-1,5-naphthyridine
-
-
8-bromo-ATP
-
-
8-bromo-ATP
-
no effect of enzyme activity in absence of spermidine, rather potent inhibitor in presence of stimulating amounts of spermidine
adenosine
-
enzyme type I is resistant, enzyme type II is inhibited
adenosine
-
IC50: 0.07 mM
adenosine
-
0.1 mM, no effect
adenosine
-
IC50: 0.09 mM
adenosine
-
0.5 mM, 67% inhibition
adenosine
-
10 mM, 30% inhibition; no inhibition
adenosine
-
IC50: 0.15 mM
adenosine
-
inhibits in the millimolar range
adenosine
-
35% inhibition at 1 mM, 20% inhibition at 4 mM and above, enzyme form QI and QII
adenosine
-
IC50: 0.07 mM. 1 mM, 93% inhibition
ADP
-
-
ADP
-
up to 0.1 mM, no effect
ADP
-
0.5 mM, 58% inhibition
ADP
-
inhibition of mPIK-I and mPIK-III
ADP
-
0.5 mM, 77.4% inhibition
ADP
-
5 mM, 90% inhibition
ADP
-
IC50: 0.12 mM. 1 mM, 92% inhibition
AMP
-
-
AMP
-
0.5 mM, 70.8% inhibition
AMP
-
1 mM, 48% inhibition
artesunate
-
-
ATP
-
-
ATPgammaS
-
-
ATPgammaS
-
5 mM 90% inhibition
BQR695
-
BRD73842
-
-
Ca2+
-
inhibited by high Ca2+ concentrations
Ca2+
-
reversibly inhibited by free Ca2+ in the nanomolar and low micromolar range, dependening on the concentration of Mg2+
Ca2+
-
0.3 mM, 50% inhibition. Increasing Mg2+ concentrations antagonize this inhibition
Ca2+
-
0.01 mM, 90% inhibition
Ca2+
-
0.01 mM to 1 mM: no effect
Ca2+
-
inhibits in the presence of Mg2+
Ca2+
-
inhibition depends in Ca2+ concentration
Ca2+
-
competitive inhibitor of Mg2+
Ca2+
-
10 mM, 50% inhibition
Ca2+
-
inhibits Mg2+-stimulated activity, IC50: 0.4 mM
Ca2+
-
inhibits in the presence of Mg2+
Ca2+
-
inhibitory at millimolar concentrations
cAMP
-
-
cAMP
-
0.5 mM, 32% inhibition
cAMP
-
0.5 mM, 10.8% inhibition
CDP
-
-
CDP
-
0.5 mM, 72.8% inhibition
Chloroquine
-
-
CTP
-
-
CTP
-
0.5 mM, 38% inhibition
deoxycholate
-
-
deoxycholate
-
10 mM, 35% inhibition
deoxycholate
-
complete inhibition at 0.5 mM
F-
-
-
GDP
-
0.5 mM, 4% inhibition
GDP
-
1 mM, 27% inhibition
GTP
-
-
GTP
-
1 mM, 24% inhibition
K+
-
-
KDU691
complete inhibition at 0.01 mM
LY294002
-
treatment inhibits SARS-CoV S-mediated entry into VeroE6 cells
Mg2+
-
above 20 mM PI kinase I and II are inhibited. PI kinase III is only slightly inhibited at 50 mM
Mg2+
-
inhibitory at concentrations above 5 mM
MMV390048
complete inhibition at 0.01 mM
Mn2+
-
above 0.5 mM
N,N-dimethyl-8-(pyridin-4-yl)-1,5-naphthyridin-2-amine
-
-
N,N-dimethyl-8-(pyridin-4-yl)-1,5-naphthyridin-2-amine
-
-
N-(2-hydroxyethyl)-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
-
-
N-(2-hydroxyethyl)-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
-
-
N-(2-hydroxyethyl)-3-[8-[4-(trifluoromethoxy)phenyl]-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
-
-
N-(2-hydroxyethyl)-3-[8-[4-(trifluoromethoxy)phenyl]-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
-
-
N-(3-aminopropyl)-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
-
-
N-(3-aminopropyl)-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
-
-
N-(3-hydroxypropyl)-4-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
-
-
N-(3-hydroxypropyl)-4-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
-
-
N-(4-chlorophenyl)-N-methyl-3-[4-(methylcarbamoyl)phenyl]imidazo[1,2-a]pyrazine-6-carboxamide
-
KDU691
N-(4-chlorophenyl)-N-methyl-3-[4-(methylcarbamoyl)phenyl]imidazo[1,2-a]pyrazine-6-carboxamide
-
KDU691
N-benzyl-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
-
-
N-benzyl-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
-
-
N-cyclopropyl-8-(pyridin-4-yl)-1,5-naphthyridin-2-amine
-
-
N-cyclopropyl-8-(pyridin-4-yl)-1,5-naphthyridin-2-amine
-
-
N-[(2S)-1-hydroxypropan-2-yl]-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
-
-
N-[(2S)-1-hydroxypropan-2-yl]-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
-
-
N-[(oxetan-3-yl)methyl]-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
-
-
N-[(oxetan-3-yl)methyl]-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
-
-
N-[2-(dimethylamino)ethyl]-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzamide
-
-
N-[2-(dimethylamino)ethyl]-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzamide
-
-
N-[2-(morpholin-4-yl)ethyl]-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
-
-
N-[2-(morpholin-4-yl)ethyl]-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
-
-
N-[2-(piperidin-1-yl)ethyl]-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzamide
-
-
N-[2-(piperidin-1-yl)ethyl]-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzamide
-
-
N-[2-(pyrrolidin-1-yl)ethyl]-3-[8-[2-(trifluoromethyl)pyridin-4-yl]-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
-
-
N-[2-(pyrrolidin-1-yl)ethyl]-3-[8-[2-(trifluoromethyl)pyridin-4-yl]-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
-
-
N-[3-(methylsulfonyl)phenyl]-8-(pyridin-4-yl)-1,5-naphthyridin-2-amine
-
-
N-[3-(methylsulfonyl)phenyl]-8-(pyridin-4-yl)-1,5-naphthyridin-2-amine
-
-
N-[3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]phenyl]methanesulfonamide
-
-
N-[3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]phenyl]methanesulfonamide
-
-
N-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]methanesulfonamide
-
-
N-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]methanesulfonamide
-
-
N6-dimethylamine-adenosine 5'-triphosphate
-
-
N6-dimethylamine-adenosine 5'-triphosphate
-
no effect of enzyme activity in absence of spermidine, rather potent inhibitor in presence of stimulating amounts of spermidine
Na+
-
-
NaCl
-
slight inhibition
NaF
-
60 mM, 73% inhibition
NaF
-
70% inhibition at 1 mM, complete inhibition at 10 mM
NEM
-
0.1 mM, complete loss of activity
NEM
-
5 mM, complete inhibition
NEM
-
0.1 mM, 42% inhibition
PCMB
-
0.01 mM, 74% inhibition
PCMB
-
0.1 mM, complete loss of activity
PCMB
-
5 mM, complete inhibition
PCMB
-
0.1 mM, 98% inhibition
Phenylarsine oxide
-
0.01 mM
Phenylarsine oxide
-
specific inhibitor
Phenylarsine oxide
-
partial inhibition at 0.01 mM
Phenylarsine oxide
-
0.1 mM, strong imhibition
Phenylarsine oxide
-
IC50: 0.001-0.005 mM; IC50: 0.03 mM; IC50: above 0.1 mM
phosphatidylcholine
-
inhibits type 3 kinase more strongly than type 2 kinase
phosphatidylcholine
-
0.6 mM, 45% inhibition
phosphatidylethanolamine
-
-
phosphatidylethanolamine
-
0.1 mM, 24% inhibition
phosphatidylethanolamine
-
0.6 mM, 67% inhibition
phosphatidylglycerol
-
0.1 mM, 63% inhibition
phosphatidylglycerol
-
0.6 mM, 68% inhibition
phosphatidylinositol 4,5-bisphosphate
-
0.5 mg/ml, 59% inhibition
phosphatidylinositol 4,5-bisphosphate
-
50% inhibition when added in equimolar amounts to phosphatidylinositol
phosphatidylinositol 4,5-bisphosphate
-
-
phosphatidylinositol 4,5-bisphosphate
-
0.6 mM, 50% inhibition
phosphatidylinositol 4-phosphate
-
-
phosphatidylinositol 4-phosphate
-
0.5 mg/ml, 42% inhibition
phosphatidylinositol 4-phosphate
-
-
phosphatidylinositol 4-phosphate
-
0.6 mM, 80% inhibition
phosphatidylserine
-
0.5 mg/ml, 64.3% inhibition of mPIK-III
phosphatidylserine
-
0.1 mM, 33% inhibition
phosphatidylserine
-
0.6 mM, 28% inhibition
PIK93
-
90% inhibition at 250 nM
quercetin
-
IC50: 0.004 mM
quercetin
-
1 mM, 36% inhibition
T-00127-HEV1
-
about 80% residual activity at 0.001 mM
Triton X-100
-
enzyme type I is inhibited at concentrations above 0.2%
Triton X-100
-
0.3% v/v, 30% decrease of activity
Triton X-100
-
inhibits activity of mPIK-I but rather weakly enhances mPIK-III activity
Triton X-100
-
above 0.4% w/v
Triton X-100
-
0.2%, 11% inhibition
UTP
-
-
UTP
-
0.5 mM, 69% inhibition
Wortmannin
-
0.03 mM
Wortmannin
-
type II enzyme is inhibited by low concentrations, type III enzyme requires mM concentrations for inhibition
Wortmannin
-
0.01 mM, complete inhibition
Wortmannin
-
treatment inhibits SARS-CoV S-mediated entry into VeroE6 cells
Wortmannin
IC50: about 300 nM
Wortmannin
-
0.01 mM, significant inhibition
Wortmannin
-
IC50: 0.05-0.3 mM; IC50: 50-300 nM
Wortmannin
-
inhibitor of type III PI4Ks
Wortmannin
-
IC50 for QI is approximately 0.007 mM, enzyme form QII is inhibited 30% at 0.01 mM
[5-(4-[[4-(morpholin-4-yl)phenyl]amino]quinazolin-6-yl)furan-2-yl]methanol
-
i.e. AL-9
[5-(4-[[4-(morpholin-4-yl)phenyl]amino]quinazolin-6-yl)furan-2-yl]methanol
-
i.e. AL-9, a 4-anilino quinazoline, inhibits purified PI4KIIIalpha and, to a lesser extent, PI4KIIIbeta, and inhibits PI4KIIIalpha in vivo
additional information
-
no inhibitory effect at 1 mM wortmannin
-
additional information
-
not inhibited by LY294002
-
additional information
-
some anti-viral molecules are isoform selective phosphatidylinositol 4-kinase inhibitors. Isozymes PI4KIIalpha and PI4KIIbeta are wortmannin-insensitive
-
additional information
-
MDL-860 does not affect in vitro isoform PI4KB activity
-
additional information
-
resistant to wortmannin
-
additional information
-
not affected by amyloid beta protein 20-29 and amyloid beta protein 31-35 alone, but both proteins are able to recover amyloid beta protein 25-35- or amyloid beta protein 2-42-induced inhibition at 0.1-5 nM
-
additional information
-
insensitive to inhibition by wortmannin
-
additional information
-
insensitive to wortmannin and LY-294002
-
additional information
-
not affected by adenosine
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.000021
(1'R)-2'-acetyl-N-(2-fluorophenyl)-1'-(hydroxymethyl)-7'-methoxy-1',2',3',9'-tetrahydrospiro[piperidine-4,4'-pyrido[3,4-b]indole]-1-carboxamide
0.0000415
(1-((5-(6-chloro-8-(((2-ethylpyridin-4-yl)methyl)amino)-2-methylimidazo[1,2-b]pyridazin-3-yl)-2-methoxyphenyl)sulfonyl)-piperidin-4-yl)methanol
Homo sapiens
pH and temperature not specified in the publication
0.000187
(3R)-1-[3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonyl]pyrrolidin-3-ol
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.000023
(4-[5-amino-6-[4-(trifluoromethyl)phenyl]pyrazin-2-yl]phenyl)(piperazin-1-yl)methanone
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.000029
1-[3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonyl]piperidin-4-ol
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.00109
1-[3-[9-(3,4-dimethoxyphenyl)-8-methyl-6-[[2-(morpholin-4-yl)ethyl]amino]-9H-purin-2-yl]phenyl]-2-methylpropan-1-one
Homo sapiens
-
isoform PI4K IIIbeta, pH and temperature not specified in the publication
0.0000062
1-[5-(6-chloro-8-[[(2-ethylpyridin-4-yl)methyl]amino]-2-methylimidazo[1,2-b]pyridazin-3-yl)-2-methoxybenzene-1-sulfonyl]piperidin-4-ol
Homo sapiens
pH and temperature not specified in the publication
0.001
2-(4-methylpiperazin-1-yl)-8-(pyridin-4-yl)-1,5-naphthyridine
Plasmodium falciparum
-
IC50 above 0.001 mM, pH and temperature not specified in the publication
0.000084
2-([3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]phenyl]sulfonyl)ethanol
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.00012 - 0.0014
2-amino-1-(isopropylsulfonyl)-6-benzimidazole phenylketone oxime
0.001755
2-fluoro-5-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.003668
2-[3-(benzylsulfanyl)phenyl]-8-(pyridin-4-yl)-1,5-naphthyridine
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.00091
2-[3-(methylsulfonyl)phenyl]-8-(piperazin-1-yl)-1,5-naphthyridine
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.000147
2-[3-(methylsulfonyl)phenyl]-8-(pyridin-4-yl)-1,5-naphthyridine
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.001432
2-[3-(piperidine-1-sulfonyl)phenyl]-8-(pyridin-4-yl)-1,5-naphthyridine
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.000046
2-[3-[(3R,5S)-3,5-dimethylpiperazine-1-sulfonyl]phenyl]-8-(pyridin-4-yl)-1,5-naphthyridine
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.005
2-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
Plasmodium falciparum
-
IC50 above 0.005 mM, pH and temperature not specified in the publication
0.0000035
2-[[7-(3,4-dimethoxyphenyl)quinoxalin-2-yl]amino]-N-methylacetamide
0.0000337
3-(6-chloro-2-methyl-8-[[(2-methylpyridin-4-yl)methyl]amino]imidazo[1,2-b]pyridazin-3-yl)-N,N-dimethylbenzene-1-sulfonamide
Homo sapiens
pH and temperature not specified in the publication
0.0000746 - 0.0001454
3-(6-chloro-2-methyl-8-[[(pyridin-3-yl)methyl]amino]imidazo[1,2-b]pyridazin-3-yl)-N,N-dimethylbenzene-1-sulfonamide
0.0000264
3-(6-chloro-2-methyl-8-[[(pyridin-4-yl)methyl]amino]imidazo[1,2-b]pyridazin-3-yl)-N,N-dimethylbenzene-1-sulfonamide
Homo sapiens
pH and temperature not specified in the publication
0.0000125
3-(6-chloro-8-[[(2-ethylpyridin-4-yl)methyl]amino]-2-methylimidazo[1,2-b]pyridazin-3-yl)-N,N-dimethylbenzene-1-sulfonamide
Homo sapiens
pH and temperature not specified in the publication
0.000719
3-(8-phenyl-1,5-naphthyridin-2-yl)benzenesulfonamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.000215 - 0.000277
3-[8-(1H-pyrazol-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
0.000091 - 0.000105
3-[8-(3-fluoropyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
0.000728
3-[8-(4-benzylpiperazin-1-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.000437 - 0.000727
3-[8-(4-methylpiperazin-1-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
0.000084
3-[8-(6-methylpyridin-3-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.000119 - 0.000238
3-[8-(pyridin-3-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
0.000025 - 0.000031
3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]-N-[2-(pyrrolidin-1-yl)ethyl]benzene-1-sulfonamide
0.000935
3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]aniline
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.000745
3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.000122
3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.000063 - 0.000102
3-[8-[2-(trifluoromethyl)pyridin-4-yl]-1,5-naphthyridin-2-yl]benzenesulfonamide
0.000265
3-[8-[4-(trifluoromethyl)phenyl]-1,5-naphthyridin-2-yl]benzenesulfonamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.005
4-fluoro-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzamide
Plasmodium falciparum
-
IC50 above 0.005 mM, pH and temperature not specified in the publication
0.005
4-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
Plasmodium falciparum
-
IC50 above 0.005 mM, pH and temperature not specified in the publication
0.00237
4-[9-(3,4-dimethoxyphenyl)-8-methyl-6-[[2-(morpholin-4-yl)ethyl]amino]-9H-purin-2-yl]phenol
Homo sapiens
-
isoform PI4K IIIbeta, pH and temperature not specified in the publication
0.0000273
5-(6-chloro-8-[[(2-ethylpyridin-4-yl)methyl]amino]-2-methylimidazo[1,2-b]pyridazin-3-yl)-2-methoxy-N,N-dimethylbenzene-1-sulfonamide
Homo sapiens
pH and temperature not specified in the publication
0.0000172
5-(6-chloro-8-[[(2-ethylpyridin-4-yl)methyl]amino]-2-methylimidazo[1,2-b]pyridazin-3-yl)-2-methoxy-N-(2-methoxyethyl)benzene-1-sulfonamide
Homo sapiens
pH and temperature not specified in the publication
0.0000086
5-(6-chloro-8-[[(2-ethylpyridin-4-yl)methyl]amino]-2-methylimidazo[1,2-b]pyridazin-3-yl)-2-methoxy-N-(prop-2-en-1-yl)benzene-1-sulfonamide
Homo sapiens
pH and temperature not specified in the publication
0.0000053
5-(6-chloro-8-[[(2-ethylpyridin-4-yl)methyl]amino]-2-methylimidazo[1,2-b]pyridazin-3-yl)-N-(1-hydroxybutan-2-yl)-2-methoxybenzene-1-sulfonamide
Homo sapiens
pH and temperature not specified in the publication
0.0000061 - 0.0134
5-(6-chloro-8-[[(2-ethylpyridin-4-yl)methyl]amino]-2-methylimidazo[1,2-b]pyridazin-3-yl)-N-(2-hydroxyethyl)-2-methoxybenzene-1-sulfonamide
0.000056
5-(6-chloro-8-[[(2-ethylpyridin-4-yl)methyl]amino]-2-methylimidazo[1,2-b]pyridazin-3-yl)-N-cyclopropyl-2-methoxybenzene-1-sulfonamide
Homo sapiens
pH and temperature not specified in the publication
0.000009 - 0.001128
5-(6-chloro-8-[[(2-ethylpyridin-4-yl)methyl]amino]-2-methylimidazo[1,2-b]pyridazin-3-yl)-N-[2-(dimethylamino)ethyl]-2-methoxybenzene-1-sulfonamide
0.0000034
5-[4-(methylsulfonyl)phenyl]-6'-(trifluoromethyl)-3,3'-bipyridin-2-amine
0.000543
5-[8-(1H-pyrazol-4-yl)-1,5-naphthyridin-2-yl]pyridine-3-sulfonamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.000424
5-[8-(4-cyanophenyl)-1,5-naphthyridin-2-yl]pyridine-3-sulfonamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.000284 - 0.000377
5-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]pyridine-3-sulfonamide
0.000355
5-[8-[4-(trifluoromethoxy)phenyl]-1,5-naphthyridin-2-yl]pyridine-3-sulfonamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.000441
6-chloro-N-[(2-ethylpyridin-4-yl)methyl]-3-(4-methoxyphenyl)-2-methylimidazo[1,2-b]pyridazin-8-amine
Homo sapiens
pH and temperature not specified in the publication
0.0000191
6-chloro-N-[(2-ethylpyridin-4-yl)methyl]-3-[4-methoxy-3-(1H-pyrazole-1-sulfonyl)phenyl]-2-methylimidazo[1,2-b]pyridazin-8-amine
Homo sapiens
pH and temperature not specified in the publication
0.000176
6-chloro-N-[(2-ethylpyridin-4-yl)methyl]-3-[4-methoxy-3-(morpholine-4-sulfonyl)phenyl]-2-methylimidazo[1,2-b]pyridazin-8-amine
Homo sapiens
pH and temperature not specified in the publication
0.0000592
6-chloro-N-[(2-ethylpyridin-4-yl)methyl]-3-[4-methoxy-3-(piperidine-1-sulfonyl)phenyl]-2-methylimidazo[1,2-b]pyridazin-8-amine
Homo sapiens
pH and temperature not specified in the publication
0.001484
8-(pyridin-4-yl)-2-[3-(pyrrolidin-1-ylsulfonyl)phenyl]-1,5-naphthyridine
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.001
8-(pyridin-4-yl)-2-[5-(trifluoromethyl)pyridin-3-yl]-1,5-naphthyridine
Plasmodium falciparum
-
IC50 above 0.001 mM, pH and temperature not specified in the publication
0.0052
8-bromo-9-(3,4-dimethoxyphenyl)-2-methyl-N-[2-(morpholin-4-yl)ethyl]-9H-purin-6-amine
Homo sapiens
-
isoform PI4K IIIbeta, pH and temperature not specified in the publication
0.00091
9-(3,4-dimethoxyphenyl)-2,8-dimethyl-N-[2-(morpholin-4-yl)ethyl]-5,9-dihydro-4H-purin-6-amine
Homo sapiens
-
isoform PI4K IIIbeta, pH and temperature not specified in the publication
0.00191
9-(3,4-dimethoxyphenyl)-2-ethynyl-8-methyl-N-[2-(morpholin-4-yl)ethyl]-9H-purin-6-amine
Homo sapiens
-
isoform PI4K IIIbeta, pH and temperature not specified in the publication
0.00299
9-(3,4-dimethoxyphenyl)-2-methoxy-8-methyl-N-[2-(morpholin-4-yl)ethyl]-9H-purin-6-amine
Homo sapiens
-
isoform PI4K IIIbeta, pH and temperature not specified in the publication
0.00207
9-(3,4-dimethoxyphenyl)-8-methyl-6-[[2-(morpholin-4-yl)ethyl]amino]-9H-purine-2-carbonitrile
Homo sapiens
-
isoform PI4K IIIbeta, pH and temperature not specified in the publication
0.00161
9-(3,4-dimethoxyphenyl)-8-methyl-N-[2-(morpholin-4-yl)ethyl]-9H-purin-6-amine
Homo sapiens
-
isoform PI4K IIIbeta, pH and temperature not specified in the publication
0.00144
9-(3,4-dimethoxyphenyl)-8-methyl-N6-[2-(morpholin-4-yl)ethyl]-9H-purine-2,6-diamine
Homo sapiens
-
isoform PI4K IIIbeta, pH and temperature not specified in the publication
0.12
ADP
Sus scrofa
-
IC50: 0.12 mM. 1 mM, 92% inhibition
0.0000035
BQR695
Plasmodium vivax
-
pH and temperature not specified in the publication
0.000021
BRD73842
Plasmodium vivax
-
pH and temperature not specified in the publication
0.000024
Cpd 6
Homo sapiens
-
isozyme PI4KIIIbeta, pH and temperature not specified in the publication
-
0.0000015
KDU691
Plasmodium vivax
-
pH and temperature not specified in the publication
4
MES
Bos taurus
-
IC50: 4 mM
0.5
MgADP-
Saccharomyces cerevisiae
-
IC50: 0.5 mM
0.000054
MI14
Homo sapiens
pH and temperature not specified in the publication
0.0000034
MMV390048
Plasmodium vivax
-
pH and temperature not specified in the publication
0.001
N,N-dimethyl-8-(pyridin-4-yl)-1,5-naphthyridin-2-amine
Plasmodium falciparum
-
IC50 above 0.001 mM, pH and temperature not specified in the publication
0.0001633
N-(2-((3-(3-((1H-pyrazol-1-yl)sulfonyl)-4-methoxyphenyl)-6-chloro-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)ethyl)-acetamide
Homo sapiens
pH and temperature not specified in the publication
0.0000269 - 0.00066
N-(2-((3-(3-(N-(4-aminocyclohexyl)sulfamoyl)-4-methoxyphenyl)-6-chloro-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)ethyl)-acetamide
0.0000199
N-(2-((3-(3-(N-allylsulfamoyl)-4-methoxyphenyl)-6-chloro-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)ethyl)acetamide
Homo sapiens
pH and temperature not specified in the publication
0.0000149 - 0.00819
N-(2-((6-chloro-3-(3-((4-(hydroxymethyl)piperidin-1-yl)sulfonyl)-4-methoxyphenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)-ethyl)acetamide
0.0000024
N-(2-((6-chloro-3-(3-(N,N-dimethylsulfamoyl)-4-methoxyphenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)ethyl)acetamide
Homo sapiens
pH and temperature not specified in the publication
0.00000723 - 0.01228
N-(2-((6-chloro-3-(3-(N-(1-hydroxybutan-2-yl)sulfamoyl)-4-methoxyphenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)ethyl)-acetamide
0.00486 - 0.0935
N-(2-((6-chloro-3-(3-(N-(2-(dimethylamino)ethyl)sulfamoyl)-4-methoxyphenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)-ethyl)acetamide
0.000022
N-(2-((6-chloro-3-(3-(N-(2-hydroxyethyl)sulfamoyl)-4-methoxyphenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)ethyl)-acetamide
Homo sapiens
pH and temperature not specified in the publication
0.0001058
N-(2-((6-chloro-3-(3-(N-cyclopropylsulfamoyl)-4-methoxyphenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)ethyl)acetamide
Homo sapiens
pH and temperature not specified in the publication
0.00000098 - 0.048
N-(2-((6-chloro-3-(4-methoxy-3-(morpholinosulfonyl)phenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)ethyl)acetamide
0.0001348
N-(2-((6-chloro-3-(4-methoxy-3-(N-(2-methoxyethyl)sulfamoyl)-phenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)ethyl)-acetamide
Homo sapiens
pH and temperature not specified in the publication
0.0001469 - 0.01707
N-(2-((6-chloro-3-(4-methoxy-3-(N-methyl-N-(2-(methylamino)-ethyl)sulfamoyl)phenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)-amino)ethyl)acetamide
0.0001894
N-(2-((6-chloro-3-(4-methoxy-3-(piperidin-1-ylsulfonyl)phenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)ethyl)acetamide
Homo sapiens
pH and temperature not specified in the publication
0.000019 - 0.000022
N-(2-hydroxyethyl)-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
0.000412 - 0.000457
N-(2-hydroxyethyl)-3-[8-[4-(trifluoromethoxy)phenyl]-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
0.000708
N-(3-aminopropyl)-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.00618
N-(3-hydroxypropyl)-4-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.0000157 - 0.000553
N-(4-aminocyclohexyl)-5-(6-chloro-8-[[(2-ethylpyridin-4-yl)methyl]amino]-2-methylimidazo[1,2-b]pyridazin-3-yl)-2-methoxybenzene-1-sulfonamide
0.0000015
N-(4-chlorophenyl)-N-methyl-3-[4-(methylcarbamoyl)phenyl]imidazo[1,2-a]pyrazine-6-carboxamide
0.00012
N-(4-cyanophenyl)-N-methyl-3-[4-(trifluoromethyl)phenyl]imidazo[1,2-a]pyrazine-6-carboxamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.000019 - 0.0011
N-(5-[4-chloro-3-[(2-hydroxyethyl)sulfamoyl]phenyl]-4-methyl-1,3-thiazol-2-yl)acetamide
0.000031 - 0.000065
N-benzyl-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
0.001
N-cyclopropyl-8-(pyridin-4-yl)-1,5-naphthyridin-2-amine
Plasmodium falciparum
-
IC50 above 0.001 mM, pH and temperature not specified in the publication
0.001015
N-[(2S)-1-hydroxypropan-2-yl]-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.000203
N-[(oxetan-3-yl)methyl]-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.002623
N-[2-(dimethylamino)ethyl]-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.00005
N-[2-(morpholin-4-yl)ethyl]-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.00136
N-[2-(piperidin-1-yl)ethyl]-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.00002 - 0.000046
N-[2-(pyrrolidin-1-yl)ethyl]-3-[8-[2-(trifluoromethyl)pyridin-4-yl]-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
0.000054 - 0.1
N-[2-([6-chloro-3-[3-(dimethylsulfamoyl)phenyl]-2-methylimidazo[1,2-b]pyridazin-8-yl]amino)ethyl]acetamide
0.000496
N-[3-(methylsulfonyl)phenyl]-8-(pyridin-4-yl)-1,5-naphthyridin-2-amine
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.000087 - 0.00011
N-[3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]phenyl]methanesulfonamide
0.00214
N-[3-[9-(3,4-dimethoxyphenyl)-8-methyl-6-[[2-(morpholin-4-yl)ethyl]amino]-9H-purin-2-yl]phenyl]acetamide
Homo sapiens
-
isoform PI4K IIIbeta, pH and temperature not specified in the publication
0.005
N-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]methanesulfonamide
Plasmodium falciparum
-
IC50 above 0.005 mM, pH and temperature not specified in the publication
0.001 - 0.1
Phenylarsine oxide
0.00045
tert-butyl N-[[8-(2-chlorophenyl)-4,5-dihydro[1,3]thiazolo[4,5-h]quinazolin-2-yl]carbamoyl]-beta-alaninate
Homo sapiens
-
isozyme PI4KIIIalpha, pH and temperature not specified in the publication
0.00057 - 0.0031
[5-(4-[[4-(morpholin-4-yl)phenyl]amino]quinazolin-6-yl)furan-2-yl]methanol
0.000021
(1'R)-2'-acetyl-N-(2-fluorophenyl)-1'-(hydroxymethyl)-7'-methoxy-1',2',3',9'-tetrahydrospiro[piperidine-4,4'-pyrido[3,4-b]indole]-1-carboxamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.000021
(1'R)-2'-acetyl-N-(2-fluorophenyl)-1'-(hydroxymethyl)-7'-methoxy-1',2',3',9'-tetrahydrospiro[piperidine-4,4'-pyrido[3,4-b]indole]-1-carboxamide
Plasmodium vivax
-
pH and temperature not specified in the publication
0.00012
2-amino-1-(isopropylsulfonyl)-6-benzimidazole phenylketone oxime
Homo sapiens
-
isozyme PI4KIIIbeta, pH and temperature not specified in the publication
0.0014
2-amino-1-(isopropylsulfonyl)-6-benzimidazole phenylketone oxime
Homo sapiens
-
isozyme PI4KIIIalpha, pH and temperature not specified in the publication
0.0000035
2-[[7-(3,4-dimethoxyphenyl)quinoxalin-2-yl]amino]-N-methylacetamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.0000035
2-[[7-(3,4-dimethoxyphenyl)quinoxalin-2-yl]amino]-N-methylacetamide
Plasmodium vivax
-
pH and temperature not specified in the publication
0.0000746
3-(6-chloro-2-methyl-8-[[(pyridin-3-yl)methyl]amino]imidazo[1,2-b]pyridazin-3-yl)-N,N-dimethylbenzene-1-sulfonamide
Homo sapiens
pH and temperature not specified in the publication
0.0001454
3-(6-chloro-2-methyl-8-[[(pyridin-3-yl)methyl]amino]imidazo[1,2-b]pyridazin-3-yl)-N,N-dimethylbenzene-1-sulfonamide
Homo sapiens
pH and temperature not specified in the publication
0.000215
3-[8-(1H-pyrazol-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.000277
3-[8-(1H-pyrazol-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.000091
3-[8-(3-fluoropyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.000105
3-[8-(3-fluoropyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.000437
3-[8-(4-methylpiperazin-1-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.000727
3-[8-(4-methylpiperazin-1-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.000119
3-[8-(pyridin-3-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.000238
3-[8-(pyridin-3-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.000025
3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]-N-[2-(pyrrolidin-1-yl)ethyl]benzene-1-sulfonamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.000031
3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]-N-[2-(pyrrolidin-1-yl)ethyl]benzene-1-sulfonamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.000063
3-[8-[2-(trifluoromethyl)pyridin-4-yl]-1,5-naphthyridin-2-yl]benzenesulfonamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.000102
3-[8-[2-(trifluoromethyl)pyridin-4-yl]-1,5-naphthyridin-2-yl]benzenesulfonamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.0000061
5-(6-chloro-8-[[(2-ethylpyridin-4-yl)methyl]amino]-2-methylimidazo[1,2-b]pyridazin-3-yl)-N-(2-hydroxyethyl)-2-methoxybenzene-1-sulfonamide
Homo sapiens
pH and temperature not specified in the publication
0.0134
5-(6-chloro-8-[[(2-ethylpyridin-4-yl)methyl]amino]-2-methylimidazo[1,2-b]pyridazin-3-yl)-N-(2-hydroxyethyl)-2-methoxybenzene-1-sulfonamide
Homo sapiens
pH and temperature not specified in the publication
0.000009
5-(6-chloro-8-[[(2-ethylpyridin-4-yl)methyl]amino]-2-methylimidazo[1,2-b]pyridazin-3-yl)-N-[2-(dimethylamino)ethyl]-2-methoxybenzene-1-sulfonamide
Homo sapiens
pH and temperature not specified in the publication
0.001128
5-(6-chloro-8-[[(2-ethylpyridin-4-yl)methyl]amino]-2-methylimidazo[1,2-b]pyridazin-3-yl)-N-[2-(dimethylamino)ethyl]-2-methoxybenzene-1-sulfonamide
Homo sapiens
pH and temperature not specified in the publication
0.0000034
5-[4-(methylsulfonyl)phenyl]-6'-(trifluoromethyl)-3,3'-bipyridin-2-amine
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.0000034
5-[4-(methylsulfonyl)phenyl]-6'-(trifluoromethyl)-3,3'-bipyridin-2-amine
Plasmodium vivax
-
pH and temperature not specified in the publication
0.000284
5-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]pyridine-3-sulfonamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.000377
5-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]pyridine-3-sulfonamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.07
adenosine
Bos taurus
-
IC50: 0.07 mM
0.07
adenosine
Sus scrofa
-
IC50: 0.07 mM. 1 mM, 93% inhibition
0.09
adenosine
Homo sapiens
-
IC50: 0.09 mM
0.15
adenosine
Saccharomyces cerevisiae
-
IC50: 0.15 mM
0.4
Ca2+
Sus scrofa
-
inhibits Mg2+-stimulated activity, IC50: 0.4 mM
5.6
Ca2+
Saccharomyces cerevisiae
-
IC50: 5.6 mM
0.05 - 0.1
Ly-294002
Saccharomyces cerevisiae
-
IC50: 0.05-0.1 mM
0.1
Ly-294002
Saccharomyces cerevisiae
-
IC50: 0.1 mM
0.0000269
N-(2-((3-(3-(N-(4-aminocyclohexyl)sulfamoyl)-4-methoxyphenyl)-6-chloro-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)ethyl)-acetamide
Homo sapiens
pH and temperature not specified in the publication
0.00066
N-(2-((3-(3-(N-(4-aminocyclohexyl)sulfamoyl)-4-methoxyphenyl)-6-chloro-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)ethyl)-acetamide
Homo sapiens
pH and temperature not specified in the publication
0.0000149
N-(2-((6-chloro-3-(3-((4-(hydroxymethyl)piperidin-1-yl)sulfonyl)-4-methoxyphenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)-ethyl)acetamide
Homo sapiens
pH and temperature not specified in the publication
0.0000438
N-(2-((6-chloro-3-(3-((4-(hydroxymethyl)piperidin-1-yl)sulfonyl)-4-methoxyphenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)-ethyl)acetamide
Homo sapiens
pH and temperature not specified in the publication
0.00819
N-(2-((6-chloro-3-(3-((4-(hydroxymethyl)piperidin-1-yl)sulfonyl)-4-methoxyphenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)-ethyl)acetamide
Homo sapiens
pH and temperature not specified in the publication
0.00000723
N-(2-((6-chloro-3-(3-(N-(1-hydroxybutan-2-yl)sulfamoyl)-4-methoxyphenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)ethyl)-acetamide
Homo sapiens
pH and temperature not specified in the publication
0.01228
N-(2-((6-chloro-3-(3-(N-(1-hydroxybutan-2-yl)sulfamoyl)-4-methoxyphenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)ethyl)-acetamide
Homo sapiens
pH and temperature not specified in the publication
0.00486
N-(2-((6-chloro-3-(3-(N-(2-(dimethylamino)ethyl)sulfamoyl)-4-methoxyphenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)-ethyl)acetamide
Homo sapiens
pH and temperature not specified in the publication
0.0935
N-(2-((6-chloro-3-(3-(N-(2-(dimethylamino)ethyl)sulfamoyl)-4-methoxyphenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)-ethyl)acetamide
Homo sapiens
pH and temperature not specified in the publication
0.00000098
N-(2-((6-chloro-3-(4-methoxy-3-(morpholinosulfonyl)phenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)ethyl)acetamide
Homo sapiens
pH and temperature not specified in the publication
0.048
N-(2-((6-chloro-3-(4-methoxy-3-(morpholinosulfonyl)phenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)amino)ethyl)acetamide
Homo sapiens
pH and temperature not specified in the publication
0.0001469
N-(2-((6-chloro-3-(4-methoxy-3-(N-methyl-N-(2-(methylamino)-ethyl)sulfamoyl)phenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)-amino)ethyl)acetamide
Homo sapiens
pH and temperature not specified in the publication
0.01707
N-(2-((6-chloro-3-(4-methoxy-3-(N-methyl-N-(2-(methylamino)-ethyl)sulfamoyl)phenyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)-amino)ethyl)acetamide
Homo sapiens
pH and temperature not specified in the publication
0.000019
N-(2-hydroxyethyl)-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.000022
N-(2-hydroxyethyl)-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzenesulfonamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.000412
N-(2-hydroxyethyl)-3-[8-[4-(trifluoromethoxy)phenyl]-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.000457
N-(2-hydroxyethyl)-3-[8-[4-(trifluoromethoxy)phenyl]-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.0000157
N-(4-aminocyclohexyl)-5-(6-chloro-8-[[(2-ethylpyridin-4-yl)methyl]amino]-2-methylimidazo[1,2-b]pyridazin-3-yl)-2-methoxybenzene-1-sulfonamide
Homo sapiens
pH and temperature not specified in the publication
0.000553
N-(4-aminocyclohexyl)-5-(6-chloro-8-[[(2-ethylpyridin-4-yl)methyl]amino]-2-methylimidazo[1,2-b]pyridazin-3-yl)-2-methoxybenzene-1-sulfonamide
Homo sapiens
pH and temperature not specified in the publication
0.0000015
N-(4-chlorophenyl)-N-methyl-3-[4-(methylcarbamoyl)phenyl]imidazo[1,2-a]pyrazine-6-carboxamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.0000015
N-(4-chlorophenyl)-N-methyl-3-[4-(methylcarbamoyl)phenyl]imidazo[1,2-a]pyrazine-6-carboxamide
Plasmodium vivax
-
pH and temperature not specified in the publication
0.000019
N-(5-[4-chloro-3-[(2-hydroxyethyl)sulfamoyl]phenyl]-4-methyl-1,3-thiazol-2-yl)acetamide
Homo sapiens
-
isozyme PI4KIIIbeta, pH and temperature not specified in the publication
0.0011
N-(5-[4-chloro-3-[(2-hydroxyethyl)sulfamoyl]phenyl]-4-methyl-1,3-thiazol-2-yl)acetamide
Homo sapiens
-
isozyme PI4KIIIalpha, pH and temperature not specified in the publication
0.000031
N-benzyl-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.000065
N-benzyl-3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.00002
N-[2-(pyrrolidin-1-yl)ethyl]-3-[8-[2-(trifluoromethyl)pyridin-4-yl]-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.000046
N-[2-(pyrrolidin-1-yl)ethyl]-3-[8-[2-(trifluoromethyl)pyridin-4-yl]-1,5-naphthyridin-2-yl]benzene-1-sulfonamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.000054
N-[2-([6-chloro-3-[3-(dimethylsulfamoyl)phenyl]-2-methylimidazo[1,2-b]pyridazin-8-yl]amino)ethyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.1
N-[2-([6-chloro-3-[3-(dimethylsulfamoyl)phenyl]-2-methylimidazo[1,2-b]pyridazin-8-yl]amino)ethyl]acetamide
Homo sapiens
pH and temperature not specified in the publication
0.1
N-[2-([6-chloro-3-[3-(dimethylsulfamoyl)phenyl]-2-methylimidazo[1,2-b]pyridazin-8-yl]amino)ethyl]acetamide
Homo sapiens
IC50 above 0.1 mM, pH and temperature not specified in the publication
0.000087
N-[3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]phenyl]methanesulfonamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.00011
N-[3-[8-(pyridin-4-yl)-1,5-naphthyridin-2-yl]phenyl]methanesulfonamide
Plasmodium falciparum
-
pH and temperature not specified in the publication
0.001 - 0.005
Phenylarsine oxide
Saccharomyces cerevisiae
-
IC50: 0.001-0.005 mM
0.03
Phenylarsine oxide
Saccharomyces cerevisiae
-
IC50: 0.03 mM
0.1
Phenylarsine oxide
Saccharomyces cerevisiae
-
IC50: above 0.1 mM
0.004
quercetin
Homo sapiens
-
IC50: 0.004 mM
0.1
quercetin
Sus scrofa
-
IC50: 0.1 mM
0.00005 - 0.0003
Wortmannin
Saccharomyces cerevisiae
-
IC50: 50-300 nM
0.0003
Wortmannin
Homo sapiens
IC50: about 300 nM
0.007
Wortmannin
Spinacia oleracea
-
IC50 for QI is approximately 0.007 mM, enzyme form QII is inhibited 30% at 0.01 mM
0.05 - 0.3
Wortmannin
Saccharomyces cerevisiae
-
IC50: 0.05-0.3 mM
0.00057
[5-(4-[[4-(morpholin-4-yl)phenyl]amino]quinazolin-6-yl)furan-2-yl]methanol
Homo sapiens
-
isozyme PI4KIIIalpha, pH 7.5, 22°C
0.0031
[5-(4-[[4-(morpholin-4-yl)phenyl]amino]quinazolin-6-yl)furan-2-yl]methanol
Homo sapiens
-
isozyme PI4KIIIbeta, pH 7.5, 22°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
evolution
-
in vertebrates, PtdIns4P is synthesized by four distinct PI4K enzymes that belong to either the type-II or type-III family, each having alpha- and beta-forms. The type-III PI4Ks are relatives of the PI 3-kinase family, while the smaller type-II enzymes form a separate family
malfunction
-
depletion of PI4KIIalpha by siRNA-mediated knockdown reduces Wnt5a-triggered uptake and/or sorting of Fz4-eGFP into EEA1-positive endosomes. This effect is fully rescued by re-expression of siRNA-resistant PI4KIIalpha
malfunction
-
depletion of PIK1 results in a subsequent loss of intracellular 1-phosphatidyl-1D-myo-inositol 4-phosphate, and loss of Pik1 induces elongated growth, because knockdown of PIK1 results in the constitutive activation of Kss1, which subsequently drives elongated growth
malfunction
-
hepatitis C virus, by recruiting PI4KIIIa in the RNA replication complex, hijacks phosphatidylinositol-4 phosphate metabolism, ultimately resulting in a markedly altered subcellular distribution of the PI4KIIIalpha product. Antiviral effect of 4-anilino quinazoline compounds is mediated by the inhibition of PI4KIIIalpha and the consequent depletion of 1-phosphatidyl-1D-myo-inositol 4-phosphate required for the HCV membranous web. Inhibition of PI4KIIIalpha by AL-9 induces the formation of large viral NS5A protein clusters
malfunction
-
in PI4KII mutants, mucin-containing glue granules fail to reach normal size, with glue protein aberrantly accumulating in enlarged Rab7-positive late endosomes. PI4KIIDELTA mutants reveal small glue granules of grossly normal morphology, PI4KIIDELTA cells also exhibited large vacuolated structures not observed in wild-type, phenotype, overview. Retromer localization and dynamics are altered in PI4KIIDELTA mutants
malfunction
-
Inhibitors of phosphatidylinositol 4-phosphate synthesis or depletion of PI4KIIIalpha, a phosphatidylinositol 4-kinase localized to the endoplasmic reticulum and Golgi, prevents the recruitment of GBF1 to Golgi membranes
malfunction
-
knockdown of isozyme phosphatidylinositol 4-kinase IIIbeta inhibits SARS-CoV S-mediated entry into VeroE6 cells
malfunction
-
mitophagy is defective in the absence of Pik1 activity, and Atg9 and Atg27 trafficking is defective in the pik1 mutant. Because Pik1 functions at the late Golgi, the defect in Atg93GFP localization to the phagophore assembly site reflects accumulation of this protein in the trans-Golgi network
malfunction
-
phosphatidic acid resulting from the phosphoinositide-dependent phospholipase C pathway is significantly lowered in a pi4kIIIbeta1beta2 double mutant exposed to cold stress, phenotype, overview. The root growth in the double mutant is 5fold reduced at 12°C
malfunction
-
PI4KIIalpha knockdown causes enlarged LAMP-1-positive endosomal structures in fixed cells. Acute depletion of phosphatidylinositol 4-phosphate in the Golgi causes accumulation of LIMP-2 in this compartment, and PI4KIIIbeta is responsible for controlling the exit of LIMP-2 from the Golgi. In contrast, depletion of PI4KIIalpha blocks trafficking at a post-Golgi compartment, leading to accumulation of LIMP-2 in enlarged endosomal vesicles. PI4KIIalpha depletion also causes secretion of missorted GBA into the medium, which is attenuated by limiting LIMP-2/GBA exit from the Golgi by PI4KIIIbeta inhibitors, overview
malfunction
-
silencing of isozyme PI4KIIIbeta, but not ofisozyme PI4KIIIa strongly inhibits SARS CoV spike-mediated entry
malfunction
-
silencing of the PI 4-kinase PI4KA leads to abberrant membranous web morphology, and PI4KB silencing inhibits HCV infection, overview. PI4KA silencing-induced membrane clustering depends on HCV polyprotein cleavage but does not require integrity of the endoplasmic reticulum-Golgi secretory pathway
malfunction
-
siRNAs that reduce PI4KA accumulation appear to perturb membranous web formation. Cell viral polyprotein expression results in enhanced cytoplasmic phosphatidylinositol 4-phosphate production. Increased phosphatidylinositol 4-phosphate accumulation following hepatitis C virus protein expression is precluded by silencing the expression of isozyme PI4KA, but not the related isozyme PI4KB. Silencing PI4KA also results in aberrant agglomeration of viral replicase proteins, including NS5A, NS5B, and NS3. NS5A alone, but not other viral proteins, stimulates phosphatidylinositol 4-phosphate production in vivo and enhanced PI4KA kinase activity in vitro
malfunction
-
an enzyme-deficient mutant displays defects in vegetative growth, deoxynivalenol production and pathogenicity. Furthermore, the deletion mutant also exhibits increased resistance to osmotic (NaCl, KCl and sorbitol), oxidative (H2O2) and cell wall (Congo Red and SDS) stresses
malfunction
-
an enzyme-deficient mutant presents serrated leaves, which is resulted from the accelerated cell division and increased auxin concentration at serration tips
malfunction
-
downregulation of enzyme expression negatively affects chilli leaf curl virus pathogenesis in Nicotiana benthamiana
malfunction
-
enzyme knockdown of isoform PI4KIIalpha -but not PI4KIIbeta - impairs toll-interleukin 1 receptor domain-containing adaptor protein and toll-like receptor 4 localization to phagosomes, reduces proinflammatory cytokine secretion, abolishes phagosomal tubule formation, and impairs major histocompatibility complex II presentation
malfunction
-
loss of the PI4K2B allele and underexpression of isoform PI4KIIbeta mRNA are associated with human cancers. Depletion of isoform PI4KIIbeta is sufficient to confer an aggressive invasive phenotype on minimally invasive HeLa and MCF-7 cell lines. Loss of isoform PI4KIIbeta induces the formation of invadopodia and leads to increased exocytic trafficking of membrane type I matrix metalloproteinase
malfunction
-
the pi4kbeta1beta2 double mutant constitutively accumulates a high salicylic acid level via isochorismate synthase 1/SID2 and this has considerable impact on other hormone levels and is associated with an increased resistance to several plant pathogens (P. syringae, H. arabidopsidis, Botrytis cinerea)
malfunction
-
mitophagy is defective in the absence of Pik1 activity, and Atg9 and Atg27 trafficking is defective in the pik1 mutant. Because Pik1 functions at the late Golgi, the defect in Atg93GFP localization to the phagophore assembly site reflects accumulation of this protein in the trans-Golgi network
-
malfunction
-
an enzyme-deficient mutant displays defects in vegetative growth, deoxynivalenol production and pathogenicity. Furthermore, the deletion mutant also exhibits increased resistance to osmotic (NaCl, KCl and sorbitol), oxidative (H2O2) and cell wall (Congo Red and SDS) stresses
-
metabolism
-
alterations to phosphatidylinositol 4-kinase expression levels can modulate MAP kinase and Akt signalling, and are important for chemoresistance, tumour angiogenesis and the suppression of apoptosis and metastases
metabolism
-
formation of PI4KII-containing endosomal tubules is independent of retromer or AP-3 function, but retromer dynamics at LEs depends on PI4KII
metabolism
-
regulation of the Golgi system and 1-phosphatidyl-1D-myo-inositol 4-phosphate levels involving the enzyme, overview
metabolism
-
regulation of the Golgi system and 1-phosphatidyl-1D-myo-inositol 4-phosphate levels involving the enzyme, overview
metabolism
-
the enzyme catalyzes the first step in generating the phosphoinositides hydrolyzed by phosphoinositide-dependent phospholipase C, EC 3.1.4.11, that produces diacylglycerol which can be phosphorylated to phosphatidic acid. Type-III PIK activity is upstream of the phosphoinositide-dependent phospholipase C activity
metabolism
-
the enzyme interacts with hepatitis C virus nonstructural protein 5A
metabolism
-
the enzyme interacts with peroxiredoxin-1, Nedd4-1, and vesicle-mediated transport proteins such as clathrin heavy chain and the pallidin subunit of BLOC-1
physiological function
-
Arabidopsis thaliana type-III phosphatidylinositol 4-kinases beta1 and beta2 are upstream of the phospholipase C pathway triggered by cold exposure, overview. De novo synthesis of 1-phosphatidyl-1D-myo-inositol 4-phosphate by PI4Ks occurs in parallel to phosphoinositide-dependent phospholipase C activation
physiological function
-
distinct phosphatidylinositol 4-kinases play important roles at multiple steps in the trafficking pathway of the LIMP-2/GBA complex. The phosphatidylinositol 4-kinases control lysosomal delivery of the Gaucher disease enzyme, beta-glucocerebrosidase, overview. Catalytic activity of PI4KIIIbeta in Golgi exit of the LIMP-2/GBA complex, which is followed by PI4KIIalpha-mediated trafficking to lysosomes. PI4KIalpha is involved in post-Golgi trafficking of LIMP-2 along the degradative pathway
physiological function
-
isozyme phosphatidylinositol 4-kinase IIIbeta is required for severe acute respiratory syndrome coronavirus spike-mediated cell entry, overview
physiological function
-
isozyme phosphatidylinositol 4-kinase IIIbeta is required for severe acute respiratory syndrome coronavirus spike-mediated cell entry. PI4P plays an essential role in SARS-CoV spike-mediated entry, which is regulated by the PI4P lipid microenvironment, overview
physiological function
-
isozyme PI4KA plays an essential role in hepatitis C virus membranous webs formation and colocalizes with the hepatitis C virus membranous webs, which show phosphatidylinositol 4-phosphate enrichment, while isozyme PI4KB supports the HCV life cycle but does not localize to or generate phosphatidylinositol 4-phosphate at membranous webs
physiological function
-
key role of isozyme PI4KIIalpha in TGN/endosomal membrane traffic, isozyme PI4KIIalpha regulates Wnt signalling, endosomal sorting of signalling receptors, and promotes adaptor protein recruitment to endosomes and the trans-Golgi network. E3 ubiquitin ligase Itch is a binding partner and regulator of PI4KIIa function. Itch directly associates with and ubiquitinates PI4KIIalpha, and both proteins co-localize on endosomes containing Wnt-activated frizzled 4 receptor. Itch and PI4KIIalpha reciprocally regulate each other
physiological function
-
phosphatidylinositol 4-kinase IIalpha is required for oxysterol binding protein-dependent activation of sphingomyelin synthesis in the Golgi apparatus, overview
physiological function
-
phosphatidylinositol 4-kinase IIalpha is required for oxysterol binding protein-dependent activation of sphingomyelin synthesis in the Golgi apparatus, overview
physiological function
-
phosphatidylinositol 4-kinases regulate vesicle mediate export from the Golgi apparatus via phosphatidylinositol 4-phosphate binding effector proteins that control vesicle budding reactions and regulate membrane dynamics. Function of phosphatidylinositol 4-phosphate at the Golgi Membrane biogenesis and lipid homeostasis
physiological function
-
phosphatidylinositol 4-kinases regulate vesicle mediate export from the Golgi apparatus via phosphatidylinositol 4-phosphate binding effector proteins that control vesicle budding reactions and regulate membrane dynamics. Function of phosphatidylinositol 4-phosphate at the Golgi Membrane biogenesis and lipid homeostasis
physiological function
-
phosphatidylinositol 4-phosphate is a key regulator of membrane trafficking. Specific requirement for PI4KII emerged in larval salivary glands. In the Golgi, PI4KII is required for sorting of glue granule cargo and the granule-associated SNARE Snap24. In endosomes, it is required for normal retromer dynamics and for formation of tubular endosomes that are likely to be involved in retrieving Snap24 and lysosomal enzyme receptor protein from late endosomes to the trans-Golgi network. PI4KII in flies thus reveals a role for PI4KII in regulating the fidelity of granule protein trafficking in secretory tissues, PI4KII catalytic activity is required for granule biogenesis and normal endosome size, overview
physiological function
-
phosphatidylinositol 4-phosphate, synthesized by phosphatidylinositol 4-kinase isozyme PI4KIIIalpha, is required for recruitment of the guanine nucleotide exchange factor GBF1 to Golgi membranes, where it is bound and activates Arf1. Activated Arf1 is required for formation of trafficking vesicles in the Golgi apparatus, overview. Rab1 contributes to the specificity and timing of GBF1 recruitment by activating PI4KIIIalpha
physiological function
-
PI4KIIalpha recruits clathrin adaptors AP1, AP3 and GGAs to the trans-Golgi network, and controls fate of endocytic vesicles, PI4KIIalpha promotes EGF receptor degradation, and supports Wnt signaling. PI4KIIIbeta regulates exit of certain cargos from the Golgi, and supports CERT-mediated ceramide transport to the trans-Golgi. PI4KIIIalpha supplies PtdIns(4,5)P2 for the plasma membrane and regulates the endoplasmic reticulum exit. Phosphatidylinositide 4-phosphate lipids are involved in viral replications. They can be used as replication platforms in the host membranes that are hijacked by RNA viruses including the endoplasmic reticulum, Golgi apparatus, trans-Golgi network, endosomes, plasma membrane and mitochondrial outer membrane. Viral replication machinery is assembled on these platforms as a supramolecular complex and PtdIns4P lipids regulate viral RNA synthesis, detailed overview. Throughout infection, the viral replication membrane platforms contain high levels of the host enzyme phosphatidylinositol 4-kinase IIIbeta, PI4KIIIbeta, that generates PtdIns4P at these membranes. PI4KIIIbeta or PI4KIIIalpha, independently from making PtdIns4P lipids, can also serve as scaffolds to recruit other host proteins to the replication platform
physiological function
-
PI4KIIIalpha is a host factor for hepatitis C virus. Isozyme PI4KIIIbet is involved in the entry of SARS coronavirus. PI4KIIIbeta is not required for virus binding and internalization, but plays a role at, or before, virus fusion with the late endosomes. Modes of recruitment of PI4KIIIs to the replication complexes of hepattis C virus, enteroviruses, and the Aichi virus, overview
physiological function
-
PI4KIIIalpha is responsible for the phosphatidylinositol-4 phosphate pool present in the plasma membrane. Antiviral effect of 4-anilino quinazoline compounds is mediated by the inhibition of PI4KIIIalpha and the consequent depletion of 1-phosphatidyl-1D-myo-inositol 4-phosphate required for the HCV membranous web
physiological function
-
PI4KIIIbeta localised to the Golgi complex through GTP-bound Arf1 binding, can be activated by protein kinase D phosphorylation, and also through interactions with neuronal calcium sensor 1. 1-Phosphatidyl-1D-myo-inositol 4-phosphate PI4P is an essential phospholipid substrate for two phosphoinositide-dependent signalling pathways that control cell migration and proliferation. It induces expression of Girdin in several cancers, and its translocation to the plasma membrane where it activates heterotrimeric Gai proteins to stimulate PI(3,4,5)P3 synthesis by PI 3-kinase, overview. The enzyme shows a potential role for a plasma membrane pool of PI4P in regulating Girdin targeting and EGFR signalling. PI4KIIIa may have an underappreciated function in the constitutive chemoresistance of cancers which are recalcitrant to apoptotic induction. PI4KIIbeta isoform migh exhibit an anti-metastatic role in hepatocellular carcinoma
physiological function
-
Pik1, a phosphatidylinositol 4-kinase that localizes primarily to the Golgi, is required for proper pheromone signaling acting independently of Ste5, overview. It also regulates MAP kinase specificity but does so independently of Ste5. Pik1 is required for full activation of the MAP kinases Fus3 and Hog1 and represses activation of Kss1. Pik1 likely regulates Ste11 and Ste50, components shared by all three MAP kinase pathways, through their interaction with the scaffold protein Opy2. Pik1 acts as a regulator of signaling specificity functioning at endomembranes rather than at the plasma membrane. Pik1 is required for full Fus3 activation and inhibits Kss1 activation. Pik1 acts via Ste11 or a pathway component downstream of Ste11, overview
physiological function
-
PtdIns 4-kinase Pik1 is involved in Atg9 trafficking through the Golgi and is involved in both nonselective and selective types of autophagy, overview. The Golgi-localized Pik1 is essential for secretory vesicle exit from the trans-Golgi network. The plasma membrane-localized Stt4 is involved in the Slt2 MAP kinase cascade and is required for autophagy. Isozymes Pik1 and Stt4 are responsible for the synthesis of the majority of cellular PtdIns4P, while isozyme Lsb6 is not essential
physiological function
-
Stt4p supplies PtdIns(4,5)P2 for the plasma membrane, regulates Pkc1 pathways and sphingolipid synthesis, and is required for cell wall integrity, Stt4p controls mitotic checkpoints. Pik1p is essentially required for late Golgi to plasma membrane secretion, and involved in cytokinesis and translation.Lsb6p can partially reverse Stt4p but not Pik1p defects, and regulates actin binding and movements of endosomes. Phosphatidylinositide 4-phosphate lipids are involved in viral replications. They can be used as replication platforms in the host membranes that are hijacked by RNA viruses including the endoplasmic reticulum, Golgi apparatus, trans-Golgi network, endosomes, plasma membrane and mitochondrial outer membrane. Viral replication machinery is assembled on these platforms as a supramolecular complex and PtdIns4P lipids regulate viral RNA synthesis, detailed overview. Throughout infection, the viral replication membrane platforms contain high levels of the host enzyme Pik1p, that generates PtdIns4P at these membranes
physiological function
-
whereas the palmitoylated membrane-bound pool is catalytically active, the cytosolic kinase is inactive
physiological function
-
isoform PI4Kgamma3 is essential for salt stress tolerance, necessary for reinforcement of plant response to abiotic stresses and delay of the floral transition. Isoform PI4Kgamma3 is activated by DNA demethylation and regulates the reactive oxygen species accumulation induced by high salt or abscisic acid treatment
physiological function
-
the enzyme is associated with actin cytoskeleton and cell adhesion, required for CD3 receptor induced calcium release, and a key component in early T cell activation signaling cascades
physiological function
-
isoform PI4Kgamma5 interacts with ANAC078 to negatively regulate auxin synthesis and hence influences cell proliferation and leaf development
physiological function
-
isoform PI4KIIalpha is an essential regulator of phagosomal toll-like receptor signaling in dendritic cells by ensuring optimal toll-interleukin 1 receptor domain-containing adaptor protein recruitment to phagosomes
physiological function
-
isoform PI4KIIbeta synthesizes a pool of 1-phosphatidyl-1D-myo-inositol 4-phosphate that maintains membrane type I matrix metalloproteinase traffic in the degradative pathway and suppresses the formation of invadopodia
physiological function
-
the enzyme is a susceptible factor, which is required by chilli leaf curl virus for pathogenesis
physiological function
-
the enzyme plays an important role for in the CO2 signal transduction pathway, that mediates PATROL1 dynamics
physiological function
-
the enzyme plays an important role in endocytosis and is involved in the pathogenicity of Fusarium graminearum. The enzyme contributes significantly to the production of deoxynivalenol and phosphatidylinositol 4-phosphate on endosomes
physiological function
-
PtdIns 4-kinase Pik1 is involved in Atg9 trafficking through the Golgi and is involved in both nonselective and selective types of autophagy, overview. The Golgi-localized Pik1 is essential for secretory vesicle exit from the trans-Golgi network. The plasma membrane-localized Stt4 is involved in the Slt2 MAP kinase cascade and is required for autophagy. Isozymes Pik1 and Stt4 are responsible for the synthesis of the majority of cellular PtdIns4P, while isozyme Lsb6 is not essential
-
physiological function
-
the enzyme plays an important role in endocytosis and is involved in the pathogenicity of Fusarium graminearum. The enzyme contributes significantly to the production of deoxynivalenol and phosphatidylinositol 4-phosphate on endosomes
-
additional information
-
hepatitis C virus stimulates the phosphatidylinositol 4-kinase III alpha-dependent phosphatidylinositol 4-phosphate production that is essential for its replication, overview. PI4KA is also implicated in HCV replication complex formation
additional information
-
molecular chaperone Hsp90 is a binding partner of isozyme PI4KIIbeta, PI4KIIbeta contains an Hsp90 interaction site, which most likely resides in the N-terminal lobe of the catalytic domain. PI4KIIbeta must bind to Hsp90 and is highly sensitive to its release, perhaps because a substantial portion of this isoform is cytosolic. Hsp90 selectively stabilizes the cytosolic pool of PI4KIIbeta.. Hsp90 protects PI4KIIbeta from degradation by the proteasome. Geldanamycin, a specific Hsp90 inhibitor, disrupts the Hsp90-PI4KIIbeta interaction and destabilizes PI4KIIbeta, reducing its half-life by 40% and increasing its susceptibility to ubiquitylation and proteasomal degradation. Cytosolic PI4KIIbeta is much more sensitive to geldanamycin treatment than is the integrally membrane-associated species. Stimuli such as PDGF receptor activation that also induce recruitment of the kinase to membranes disrupt the Hsp90-PI4KIIbeta interaction to a similar extent as inhibitor treatment. Dissociation of PI4KIIbeta from Hsp90 by exposure to geldanamycin results in transient translocation to membranes and increased kinase activity
additional information
-
molecular chaperone Hsp90 is no binding partner of isozyme PI4KIIalpha, although also PI4KIIalpha contains an Hsp90 interaction site, which most likely resides in the N-terminal lobe of the catalytic domain, but PI4KIIalpha apparently does not require stabilization by Hsp90 binding because it associates strongly with membranes, even in the absence of palmitoylation
additional information
-
nuclear accumulation of Pik1 is promoted by nutrient, e.g. glucose, deprivation, a condition that also results in the release of PI4K effectors from Golgi membranes and slowing of the rate of secretion
additional information
-
PI4KA interacts with viral protein NS5A in hepatitis C virus-infected cells
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.